Report to the New York Department of Financial Services

New York State Medical Indemnity Fund

3rd Quarter 2018 Actuarial Analysis
As of September 30, 2018

January 2018



3109 Cornelius Drive Bloomington, IL 61704 309.807.2300 pinnacleactuaries.com

TABLE OF CONTENTS

<u>Section</u>	<u>Page</u>
Purpose & Scope	1
Executive Summary	2
Background	5
Data, Methods & Assumptions	6
Discussion and Analysis	10
Number of Qualifying Participants	10
Mortality Experience/Life Expectancy	11
Actuarial Calculation of Estimated Fund Liabilities	13
Amount of Benefits Paid	
Patterns of Utilization	16
Benefit Payments and Injury Type	18
Inflationary Patterns of Types of Services	21
Administrative Expenses	21
Impact of Available Health Insurance	22
Investment Earnings	23
Distribution & Use	23
Reliances & Limitations	24

EXHIBITS

New York State Medical Indemnity Fund 3rd Quarter 2018 Actuarial Analysis As of September 30, 2018

Purpose & Scope

Pinnacle Actuarial Resources, Inc. ("Pinnacle") has been retained by the New York State Department of Financial Services (NYS DFS or "the Department") to provide quarterly actuarial reports regarding the experience of the New York State Medical Indemnity Fund (MIF or the Fund). This analysis evaluates data for the Fund as of September 30, 2018.

§69-10.19 of the New York State Department of Health Regulation states that the quarterly reports should "include a review of the various elements contributing to the amount of benefits paid by the Fund and to the expenses of administration of the Fund, including:"

- The number of qualifying plaintiffs
- The mortality experience of the qualified plaintiffs
- The amount of benefits paid by the Fund
- The patterns of utilization of types of services provided
- Inflationary patterns by types of services provided
- The expenses of administration of the Fund
- The impact of available health insurance on benefits paid by the Fund, and
- Investment earnings of the Fund

§69-10.20 of the New York State Department of Health Regulation also requires an actuarial calculation of the estimated liabilities of the Fund for the coming year resulting from the qualified plaintiffs enrolled in the Fund.

Executive Summary

Based on our review of available information regarding the New York State Medical Indemnity Fund as of September 30, 2018, Pinnacle has arrived at a number of key conclusions:

- As of September 30, 2018, the Fund has accepted 565 participants (556 living) with expected future benefit payments of approximately \$766.6 million and future administrative expenses of \$116.4 million, assuming a discount rate of 2.5%. With a Fund balance as of September 30, 2018 of approximately \$260.2 million, this results in an unfunded liability for the Fund of approximately \$622.9 million.
 - Total future lifetime benefits for the 556 living Fund participants without discounting is estimated to be \$1.964 billion. See Exhibit 2, Page 2.
 - The current present value of future benefit payments of \$766.6 million does not consider any additional enrollees that may be admitted to the Fund in the future.
 - O Prior to the impact of legislation signed on December 31 of 2016, each new participant admitted to the Fund after June 30, 2017 was expected to increase the Fund's future benefits payment liabilities by \$3.35 million on a nominal basis, or a present value of \$1.32 million, increasing at approximately the medical inflation rate of 3.5% annually from March 31, 2017.
 - On December 31, 2016, new legislation was signed expanding eligibility for the Fund to non-hospital births and significantly raising reimbursement rates for the period from July 1, 2017 through December 31, 2019. For new participants admitted during this period, a priori estimates of future lifetime benefit payment liabilities increased to \$3.62 million on a nominal basis or a present value of \$1.52 million. These liabilities vary depending on the amount of an individual participant's benefits that are paid during the period of higher reimbursement rates. As more experience has emerged, we have varied these severities based on actual benefit payments. See Exhibit 6, Page 2 for more detail.
 - Prior to the beginning of the fiscal year, the Fund was expected to have approximately ninety-two (92.02) additional participants accepted between March 31, 2018 and March 31, 2019.

- There were nineteen (19) new participants to the Fund in the second quarter of fiscal year 2018-19, approximately four (4) less than expected for this period at the beginning of the fiscal year. This difference is despite updated participant estimates evaluated at March 31, 2018 for our previous report. Prior to this quarter, new participant counts per quarter have varied between eleven (11) and twenty-eight (28) in the last two years.
- The number of eligible participants is expected to continue increasing for at least thirty years as more eligible participants are admitted to the Fund each year.
- Actual benefit payments in the second quarter of the 2018-19 fiscal year (7/1/18-9/30/18) as of 9/30/18 were \$9.255 million. This amount is \$1.760 million lower than expected at the prior quarterly analysis. Cumulative benefit payments thus far in the 2018-19 fiscal year total \$17.015 million. Based on modeled severities and an expected 46.01 additional participants, expected benefit payments in the remaining half of the 2018-19 fiscal year are \$23.086 million. Estimated total benefit payments for the 2018-19 fiscal year (4/1/18 3/31/19) are therefore \$40.101 million. See Exhibit 3 for more detail regarding these numbers. It is important to recognize that these amounts can vary significantly each quarter due to the inherent uncertainty in benefit payments, the effect of the legislative change on payments, and the transition to a new third party claim administrator in the third quarter of the 2017-18 fiscal year.
- As of September 1, 2018, both the Fund's claims handling and enrollment services are now
 performed by Public Consulting Group (PCG) instead of Alicare. This change decreases the
 administrative expenses of the Fund on a per month per member basis. Based on information
 from the Department, at the March 31, 2018 analysis we projected that \$5.036 million would
 be spent in administrative costs for the 2018-19 fiscal year. This number is likely to vary as it is
 based on expected, not actual, participant counts and it did not contemplate the change in
 enrollment services.
- Exhibit 1 summarizes Fund payments by benefit type since 4th quarter of 2012.
 Compared to the Virginia Birth Related Neurological Injury Compensation Fund, another state-run birth injury fund serviced by Pinnacle, the Fund is having a substantially higher percentage

- of overall costs in medical and hospital costs, medical equipment and prescription drug costs, and corresponding lower percentages in nursing and long term care costs.
- As of September 30, 2018, twenty-five (25) participants have received more than \$1 million in benefit payments, with seven (7) of these participants receiving more than \$2 million in benefit payments. Based on current annual severities by individual member, we expect seven (7) more members to cross the \$1 million threshold in the next twelve months. These benefit payments do not include prescription amounts handled in bulk by vendors; see Exhibit 7, page 8 for total prescription drug payments handled in bulk.

Background

"The Medical Indemnity Fund was established in 2011 to provide a funding source for future health care costs associated with birth-related neurological injuries. Enrollees of the Fund are plaintiffs in medical malpractice actions who have received either court-approved settlements or judgments deeming the plaintiffs' neurological impairments to be birth-related." More specifically, a "birth-related neurological injury" is "an injury to the brain or spinal cord...that occurred in the course of labor, delivery or resuscitation, or by the provision or non-provision of other medical services during the delivery admission." These injuries must result in a physical impairment, a developmental disability, or both.

Benefits provided by the Fund include:

- Medical, Dental, Surgical and Hospital Care
- Nursing and Custodial Care
- Prescription and Non-Prescription Drugs
- Rehabilitation Services
- Durable Medical Equipment and Assistive Technology
- Certain Home and Vehicle Modifications
- Other Health Care Costs for Medical Services and Supplies for Participants

The New York State Department of Financial Services (NYS DFS) serves as the administrator of the Fund. For the first year of the MIF's operations, Sedgwick CMS served as the Fund's third party administrators (TPA). For the second year of operations, they were replaced by Alicare. As of September 1, 2017, claims are now handled by Public Consulting Group while Alicare continued to work with Fund enrollment and case management until September 1, 2018. PCG now handles enrollment services as well as claims. Pinnacle serves as the actuarial advisors to the Fund as well as the only other two state-run birth injury funds in the U.S., the Virginia Birth Related Neurological Injury Compensation Fund and the Florida Neurological Injury Compensation Association.

¹ Provided by NY DFS

² http://www.dfs.ny.gov/insurance/mif/mif_faqs.htm

The Fund currently is financed through a budget allocation from the state of New York. Any party to a medical professional liability claim can request for the judgment to reflect eligibility for participation in the Fund. Upon this judgment, the participant is eligible to receive covered benefits from the Fund.

Data, Methods & Assumptions

Given that the Fund has been in operation for less than eight years, a number of sources of information are still in the formative stages. Pinnacle has worked with Alicare and is working with Public Consulting Group to ensure that their claims databases are sufficient to support these ongoing quarterly reports and to enhance the ongoing management of the Fund.

Early in the Fund's operations, some health care benefits that should have been paid by the Fund were erroneously paid by New York Medicaid. Pinnacle was provided detailed benefit payment information on these costs by the New York Department of Health (DOH) and they are reflected in the exhibits.

Some of the long-term forecasts and industry benchmarks used in the analysis are based on data for the birth injury funds in Virginia and Florida, as well as medical professional liability insurers in the state of New York. These have been significantly modified based on data from the Fund as it becomes more credible.

One significant area of ongoing review of assumptions relates to the expected number of claims per 10,000 live births. Initially, 1.10 participants per 10,000 births were assumed based on data from Virginia and Florida. After the first year, the frequency rate was increased to 2.90 participants per 10,000 births. In the first quarter 2014 report, the expected number of eligible Fund participants was increased from 2.90 per 10,000 live births to 3.48 to be more consistent with the first two full fiscal years of experience and present more realistic financial projections for the next five years. In late 2016, we increased the assumption to 4.50 participants per 10,000 births to better reflect ongoing frequency data. It should be recognized that this is over four times the number of participants per 10,000 live births experienced by the birth funds in Florida and Virginia. Starting with the March 31,

2018 analysis, we reduced this assumption to 4.00 participants per 10,000 births to acknowledge lower than expected Fund participation rates.

As we are accumulating more credible amounts of benefit payments data, several differences are emerging from Virginia's birth fund experience. To illustrate, we show the annual benefit payments during calendar years 2016 and 2017 to Fund participants that were admitted to the program prior to the beginning of each year (i.e. participants that have a full year of benefit payments) on the following graph and compare the Fund's data to data from Virginia. Additional severity information is contained in Exhibit 1, Page 2 and Exhibit 6.




Chart 1: Calendar Year Payments Received by Participants

In the past, this type of comparison has raised three key issues. We will pose each issue as a question, then offer more comments below.

- 1) The Fund has significantly more participants with \$0 of benefit payments. Will these participants have benefit payments at some point?
- 2) The Fund has substantially more participants with less than \$25,000 in annual benefit payments. Is there something about the Fund's enabling legislation that is causing this or will their costs increase over time?
- 3) The Fund had seven participants in 2016 and eight participants in 2017 with annual benefit payments totaling over \$400,000. Virginia's birth fund has no participants that breached this threshold. Admittedly, there are sample size issues, but will this phenomenon persist?

To address the first issue, we analyzed the 458 participants that had been in the Fund for more than one year. We found that of these participants, 8% showed \$0 in benefit payments as of March 31, 2018. Approximately 3% of participants showed only prescription drug payments. Of the remaining 406 participants, 397 participants (or 98%) had a payment within three years of joining the Fund. We also grouped participants based on number of years in the Fund and found that approximately 92% of participants in all groups have had payments:

Time in Fund	Number of Participants	Number of Participants With Payments	Percentage of Participants With Payments
3 years or longer	312	287	92.0%
2 years or longer	403	374	92.8%
Longer than 1 year	458	420	91.7%

Table 2: Participants with Payments (in the Fund longer than 1 year)

Based on the data collected so far and assuming no significant changes in health insurance, we believe it is reasonable to assume that 8% of Fund participants will not receive any benefit payments over their lifetimes. Hence while 18% of the participants in the graphs above showed \$0 in payments, we expect that over the long run only 8% of participants will receive \$0 in benefit payments.

The second issue, a higher number of participants with less than \$25K in annual payments, appears to be related to the difference in the definition of "birth-related injury" between the Fund and Virginia. In

Virginia, participants must be "permanently motorically disabled <u>and</u> developmentally disabled or cognitively disabled (emphasis added)" as well as "need assistance with all daily living activities." The New York Fund requires either a physical <u>or</u> mental disability (emphasis added); both types are not required. Several of the Fund's patients have injury diagnoses that tend to be physical-only injuries, particularly Brachial Plexus and Erb's Palsy. These injury types show significantly lower severities than other types (see Exhibit 1, Page 2); about 98% of members with one of these two conditions received less than \$25,000 in benefit payments in 2017. This does not completely explain the low severities as only 11.5% of Fund participants have one of these diagnoses. However, physical-only or mental-only disabilities classified within other injury categories may also be contributing to the low severities. For example, all fourteen members with a diagnosis of hemiplegia received less than \$25,000 each in benefit payments during calendar year 2017. We do not have the detailed diagnosis information to further explore this hypothesis.

Over the long term, we show that over 50% of participants will receive more than \$25K in benefit payments:

		Number of	Percentage of
	Number of	Participants	Participants
Time in Fund	<u>Participants</u>	With >\$25K Paid	With >\$25K Paid
3 years or longer	312	175	56.1%
2 years or longer	403	220	54.6%
Longer than 1 year	458	238	52.0%

Table 3: Participants with At Least \$25K Paid (in the Fund longer than 1 year)

The answer to this second issue also comes with a caveat. Benefit payments shown on a perparticipant basis do not yet include prescription/non-prescription drug payments currently handled in bulk by Fund vendors. Prior to changing claims handlers to PCG, approximately 75% of prescription/non-prescription drug costs were handled in bulk, but schedules were provided to allocate these costs on a per-participant basis. In the fourth quarter of the 2017-18 policy period, over 90% of

³ From vabirthinjury.com/eligibility-benefits-claims

prescription/non-prescription drug costs were handled in bulk but we have not received vendor schedules. We are working with PCG to obtain this data for future analyses.

The phenomenon mentioned in the third issue, participants with very large annual payments, has indeed persisted since 2016. In calendar year 2017, eight participants received more than \$400K in benefit payments. Over fiscal year 2017, thirteen participants in the Fund for longer than one year received over \$400,000 in benefit payments. Taking a long-term view, five of these participants show an average annual benefit cost of over \$400,000 per year of membership in the Fund. These numbers also do not yet include prescription/non-prescription drug payments handled in bulk by Fund vendors.

We are continuing to monitor these phenomena and will continue to add additional analysis as appropriate and as more information emerges.

As frequency and severity patterns were observed over time, changes to the assumptions regarding the expected frequency and severity of claims were made to the 4th quarter 2014 analysis and again in the second quarter of 2016 due to observed frequencies and severities differing from original assumptions. These assumptions are detailed above in this report. Furthermore, we expect to continue monitoring participation frequency and re-visit our selections regularly.

Discussion and Analysis

Number of Qualifying Participants

Based on the loss runs provided by Sedgwick CMS, Alicare, PCG and DOH, valued as of September 30, 2018, there are five hundred sixty-five (565) participants that have qualified for the Program as of this date; five hundred fifty-six (556) were still living as of September 30, 2018. This information is summarized in Exhibit 2.

There were nineteen (19) new participants to the Fund in the second quarter of fiscal 2018, approximately four (4) fewer than expected for the quarter. The Fund has averaged fifteen (15) new

participants per quarter over the past four quarters, in contrast to twenty (20) new participants per quarter for the four quarters prior to that. The reason for this drop is not clear, particularly as the legislation signed on December 31, 2016 expanded Fund participation to include non-hospital births.

The number of Fund participants and the distribution of participants by age warrants continued monitoring. The average age of a Fund participant at the time of admission remains at about 8.6 which is approximately four years older than the age of a Virginia Birth Fund participant at admission.




Chart 4: Average Entry Age of Fund Participants

Mortality Experience/Life Expectancy

It is reasonable to expect that average life expectancies for Fund participants will average in the high twenties as a group, unless the different admission standards materially change life expectancies relative to the Virginia and Florida birth funds. The current life expectancies of the Virginia birth fund are 28.4 years from birth and 29.1 years for participants that reach the age of three (3). As of September 30, 2018, the Fund has experienced the death of only nine (9) of its participants. Furthermore, only seventeen (17) Fund participants were admitted prior to the age of three. The following graph compares the age of current participants with the expected age distribution based on the Virginia Birth Fund data.




Chart 5: Age Distribution of Fund Participants

Due to the low number of Fund participant deaths (only 1.6% of admitted participants are deceased), we do not yet have enough credible data to compare Fund participant life expectancies with Virginia life expectancies. We hypothesize that the inclusion of physical-only and mental-only injuries may lead to higher Fund life expectancies than Virginia life expectancies, but we require more data to support or refute this hypothesis.

Actuarial Calculation of Estimated Fund Liabilities

We have been asked to project expected fund liabilities for the next ten fiscal years of the MIF. To do this, we have estimated the ultimate benefit payments for the participants admitted to the Fund each quarter on both a nominal and discounted basis. Three methods were used as a reasonability check for estimating ultimate benefit payments by the year in which a participant was accepted to the Fund. A loss development method was used in which actual benefit payments to date were divided by the expected percentage of ultimate benefits as of each participant-quarter's maturity. These percentages were developed based on information for the Virginia Birth Fund and modified to reflect the older average age of the Fund participants upon admittance. An expected loss method was also used in which expected ultimate benefit payments by quarter were also estimated using a weighted average of expected average ultimate benefit payments per Fund participant overall and by quarter of eligibility. Finally, a Bornhuetter-Ferguson (B-F) technique estimates ultimate losses using a combination of expected losses and loss development techniques. See Exhibit 6, page 1 for the application of these three techniques.

On December 31, 2016, legislation was signed expanding eligibility for the Fund to non-hospital births and significantly raising reimbursement rates for the period from July 1, 2017 through December 31, 2019. We prepared an extensive costing study in March 2017 estimating the impact of this change on participant severities based on the expected increased participation and reimbursement rates. Since that time we have relied primarily on these severities, modifying them as actual experience emerges for living participants and using the other three methods as a reasonability check. The current selected severities can be seen in Exhibit 6, Page 2.

These ultimate benefit amounts can be compared to the a priori benefit estimates (adjusted for the legislative benefit payment change) allocated to future payment quarter based on the benefits payment patterns described previously. To state future payments on a discounted basis, a discount rate of 2.5% was used. This is based on discount rates for other medical professional liability insurance programs in New York. Prior to the recent legislative change, average lifetime benefit payments were estimated to average \$3.35 million per participant on a nominal basis and \$1.32 million on a discounted basis using a 2.5% discount rate. This amount increases annually to account for the medical inflation rate of 3.5%. For new participants admitted subsequent to the law change, an a priori estimate of future lifetime benefits payment liabilities increased to an average of \$3.62 million on a nominal basis or a present value of \$1.52 million. These liabilities will vary depending on the amount of an individual participant's benefits that are paid during the period of higher reimbursement rates. For the March 31, 2018 analysis, we adjusted the severity assumptions for participants already admitted into the Fund based on Fund experience. These severities vary based on the participant's admittance year to the Fund. The timing of the payments used in our severity estimates also reflect the amount of time a participant is expected to live, so that these severities take participant mortality into account. See Exhibit 6, Page 2 for more detail on these numbers.

Based on this approach and the current legislation, we estimate that the 556 living admitted Fund participants will ultimately receive benefit payments on the order of \$2.067 billion. Adjusting for the time value of money at a 2.5% discount rate results in a present value for these benefits of \$869.0 million. See Exhibit 5, Pages 3 and 6 for more detail on these numbers.

Actual benefit payments in the second quarter of the 2018-19 fiscal year were \$9.255 million. Cumulative benefit payments thus far in the 2018-19 fiscal year total \$17.015 million. Based on modeled severities and an expected 46.01 additional participants, expected benefit payments in the remaining half of the 2018-19 fiscal year are \$23.086 million. Estimated total benefit payments for the 2018-19 fiscal year (4/1/18 - 3/31/19) are therefore \$40.101 million. See Exhibit 3 for more detail regarding these numbers. It is important to recognize that these amounts can vary significantly each quarter. The change from our estimate of \$42.092 for fiscal year 2018-19 in the prior analysis is due to

benefit payments that were lower than our expected estimate as of the June 30, 2018 analysis in the last three months as well as fewer than expected participants added in the last three months. We are continuing to monitor our estimation methodology closely as it is quite sensitive to several key assumptions.

The number of eligible participants is expected to continue increasing for at least 30 years as more eligible participants are admitted to the Fund each year.

Amount of Benefits Paid

Based on payment data provided by PCG, \$9.255 million has been paid to Fund participants during the second quarter of the 2018-19 fiscal year (7/1/18 - 9/30/18). These payments are \$1.760 million lower than the expected benefit payments as of the June 30, 2018 analysis. See Exhibit 3 for more detail.

We have investigated to see if there are material differences in the types of injuries experienced by participants in the New York Fund versus those in Virginia and Florida that may explain some of the differences we are seeing between actual and expected payments. As noted previously, the Virginia program requires both a physical and developmental/cognitive disability and the participant must "need assistance with all daily living activities" to qualify for admittance. This standard for Virginia is therefore stricter than for the Fund, which requires either a physical or mental disability but not necessarily both. This difference appears to be contributing to the Fund's higher frequency of participants per live births as well as a higher frequency of participants with less than \$25,000 in payments per year. For example, the Center for Disease Control and Prevention considers cerebral palsy a motor disability. While children with cerebral palsy often have a co-occurring physical or developmental disability, cerebral palsy can exist separately from intellectual disability. As participants with cerebral palsy account for 23% of the Fund's participants and 28% of the Fund's payments (see Exhibit 1, Page 2), this distinction could be impacting the Fund's divergence from Virginia's experience.

⁴ From vabirthinjury.com/eligibility-benefits-claims

⁵ https://www.cdc.gov/ncbddd/cp/data.html#references

In addition, we recognize that certain diagnoses tend to be "physical-only" (i.e. Brachial Plexus and Erb's Palsy). However, we do not have detailed diagnosis data nor the medical expertise that could inform further investigation.

Patterns of Utilization

It is too early in the life of the Fund to provide any credible conclusions regarding patterns of utilization. However, Pinnacle continues to work with PCG to develop the data capabilities to provide this type of analysis in the future. Specifically, we have developed and continue to maintain detailed benefit payment information by participant, diagnosis, Fund fiscal year and benefit type. The benefit types being captured are intended to reflect the benefits provided by the Fund's legislation and follow form with existing databases in Florida and Virginia.

Exhibit 1 shows payment detail (provided through 9/30/18) grouped into the following categories:

- Medical Treatment
- Hospital Based Care
- Surgical Care
- Nursing Care
- Dental Care
- Rehabilitation Care
- Custodial Care
- Durable Medical Equipment
- Home Modifications
- Vehicle Modifications
- Prescription and Non-Prescriptive Drugs
- Other Health Care Costs
- Assistive Technology
- Other Payments

Our analysis suggests benefit payment patterns that differ from the Virginia data. To date, the Fund has a substantially higher percentage of overall costs in medical and hospital costs, medical equipment and prescription drug costs, and corresponding lower percentages in nursing and long-term care costs. To improve our understanding of the prescription drug costs, PCG now provides vendor payment data that allow us to explore prescription drug costs on a by-member basis (although these summaries do

not directly map to the quarterly payment summaries and prescription drugs must still be handled in bulk for our overall analysis). This data is summarized in Exhibit 1, Page 1 and shown graphically below. Exhibit 1, Page 1 also compares New York data to benefit payments in Virginia. Nursing costs are the majority of total payments in both states.




Chart 6: Benefit Payments by Category

Another key aspect of the database needed to evaluate patterns of utilization is differences in the medical and mental condition of the Fund's participants. To facilitate this dimension of our future analysis, Pinnacle worked with Alicare to track a number of characteristics for each Fund participant, including:

- Current Age
- Gender

- Injury Description
- Other Insurance (i.e. whether participant holds other insurance)
- Ambulatory Status
- Use of a gastric feeding tube (G-Tube)
- Ability to lift head from the prone position
- Use of a ventilator
- Use of a tracheostomy tube (trach tube).

Most of these characteristics are still available through the data PCG now provides, although we have not yet been provided with the participant limitations (such as the use of a gastric feeding tube) that have been found to be valuable in the Virginia analysis. In Virginia, several of these characteristics have been shown to influence life expectancies and average annual benefit payments. While we do not have the data yet to evaluate life expectancies by diagnosis, we are continuing to compile average annual benefit payment information for all members with over 1 year of participation in the Fund and are tracking current patterns to inform future analyses.

Benefit Payments and Injury Type

For nearly all Fund participants, the nature of the injury and primary diagnosis permitting entrance into the Fund has been provided to Pinnacle as part of the quarterly enrollment data. Although strict standardization of participant injury types is not provided, sufficiently detailed descriptions of the nature of the injury have allowed us to judgmentally categorize participants into standardized injury type groups. As with the benefit type categorization, injury type categorization can aid in identifying differences in injury types that are relevant to the management of the Fund.

We have categorized the primary diagnosis for each Fund participant into one of the following injury types:

- Brachial Plexus
- Cerebral Palsy
- Developmental Delays
- Encephalopathy
- Erb's Palsy
- Hemiplegia

- Mental Retardation
- Neurological Disabilities
- Quadriplegia
- Spastic Diplegia
- Spastic Paraplegia
- Spastic Quadriplegia
- Other
- Not Available

The following is a graph of the distribution of participants by injury type group above. Spastic quadriplegia, cerebral palsy, and encephalopathy combine to make up about 72% of total benefit payments.




Chart 7: Benefit Payments by Injury Type

It is clear from the graph that the Fund's participant composition by injury type is varied, but also concentrated in a handful of categories. The following graph illustrates the number of participants and average payment by injury type through the current quarter.




Chart 8: Average To Date Payments per Participant

Participants with injury types of Cerebral Palsy, Encephalopathy or Spastic Quadriplegia comprise approximately 53% of the total participants, but account for approximately 72% of total payments, resulting in relatively large average payments. Conversely, participants with injury types of Brachial Plexus, Erb's Palsy, Spastic Diplegia, Hemiplegia, Mental Retardation, Developmental Delays or Neurological Disabilities have relatively low average payments and comprise approximately 40% of the total participants, but account for only 19% of total payments. The large number of participants in the Developmental Delays and Neurological Disabilities categories with relatively low benefit payments are also noteworthy.

Inflationary Patterns of Types of Services

It is far too early in the life of the Fund to provide any credible conclusions regarding inflationary patterns based on Fund payments alone. However, data from the Bureau of Labor Statistics provides a helpful look at the impact of inflation on medical costs in the state of New York:




Chart 9: Medical Care Inflation in the State of New York

Average inflation over the past five years is 2.9%, similar to the 3.5% inflationary rate we contemplate for the Fund's benefit payments. In addition, based on our experience in Virginia, we are confident that the detailed claims benefits payment database being constructed will prove invaluable once more benefits experience has been accumulated.

Administrative Expenses

Pinnacle was provided information in early 2017 on administrative expenses charged by Alicare to the Fund for claims administration and enrollment services. As of September 1, 2017, the claims administration was taken over by PCG while Alicare continued to service enrollment to the Fund. One year later at September 1, 2018, PCG began providing enrollment services as well in place of Alicare.

With this change in claims administration, we expect remaining administrative expenses for fiscal 2018-19 of \$2.664 million (see Income Statement on Exhibit 2, Page 1).

The Fund has made positive strides toward reducing its administrative expenses over the past year. Prior to the recent changes in claims administration, Alicare was charging the Fund \$809 per Fund participant per month. Under the current payment structure, the total administrative costs are now approximately \$770 per Fund participant per month (see Exhibit 8 for current cost estimates). This cost is set to decrease over the next five years as the addition of new participants will reduce the fixed cost per member. At the beginning of the fiscal year (March 31, 2018), we estimated \$5.036 million in administrative expenses during the upcoming 2018-2019 fiscal year. Actual administrative expenses are now expected to be lower than this estimate due to fewer new participants than expected and the recent changes to the Fund's administration programs.

Impact of Available Health Insurance

It is also far too early in the life of the Fund to provide any credible conclusions regarding the impact of available health insurance. However, the detailed benefit payment database described earlier and summarized in Exhibit 1 will prove invaluable once more payment experience has been accumulated. One early item of note is the number of participants with Medicaid has been consistently tracking at more than half of the Fund's participants. Approximately 65% of Fund participants admitted in the past four quarters rely on Medicaid, and currently 65% of all Fund participants rely on Medicaid. As shown below, average annual payments relative to time in the Fund does not differ much between members with and without insurance.

8	Participant Years	Paid Benefits	Total Severity
With Insurance	751.75	31,576,004	42,003
Without Insurance	1,293.75	63,255,385	48,893

Table 10: Participant Years of Participation and Paid Benefits, with and without Insurance

Investment Earnings

The Fund earned \$2,272,836 of investment income during the period from 4/1/17 through 3/31/18. Over that period, we estimate the Fund's average balance to be \$222,685,734 indicating a 1.0% investment return on the Fund balance. This is in contrast to the 2.5% discount rate contemplated by our analysis based on our review of other medical professional liability programs in the state of New York. We have not had the opportunity to review further information regarding the Fund's investment returns on the Fund's invested assets at this time. We hope that more information will be provided in upcoming quarterly reports. Building up investment income on the Fund's balance will be essential to the Fund's ongoing financial strength as participants continue to enter the Fund and calendar year benefit payments continue to grow as the Fund moves toward a steady state over the next twenty or more years.

Distribution & Use

This Report has been prepared for the intended use of the NY DFS. Further distribution of this report is controlled by Pinnacle's contract with the NY DFS. Third parties reviewing the report should recognize that the furnishing of this report is not a substitute for their own due diligence and should place no reliance on this report or the data contained herein that would result in the creation of any duty or liability by Pinnacle to the third party.

Pinnacle consents to reference by the Department to Pinnacle's reports, opinions, advice and firm name in documents released by or at the direction of the Department concerning such financial examination findings. In any instances other than the Department's final examination report regarding the review of reserves and solvency analysis of the Fund in which Pinnacle is identified as the source of a paraphrase, quotation or partial quotation, the Department shall notify Pinnacle prior to such publication, so that Pinnacle may review said reference(s).

The exhibits attached in support of our findings are an integral part of this Report. These sections have been prepared so that our actuarial assumptions and judgments are documented. Judgments about

the conclusions drawn in this Report should be made only after considering the Report in its entirety. We remain available to answer any questions that may arise regarding this Report. We assume that the user of this Report will seek such explanation on any matter in question.

Our conclusions are predicated on a number of assumptions as to future conditions and events. Those assumptions, which are documented in subsequent sections of this report, must be understood in order to place our conclusions in their appropriate context. In addition, our work is subject to inherent limitations, which are also discussed in this Report.

"Any and all Department communications, records, documents, written, oral or electronic communication or other information of any kind are confidential. [Pinnacle] shall not copy, transmit, deliver or communicate in any way to any other person or entity any such communications and/or information without the prior written consent of the Department."

"All information and materials received hereunder by [Pinnacle] from Department are and shall remain the sole and exclusive property of Department, and [Pinnacle] shall have no right, title or interest in or to any such information or materials by virtue of their use or possession hereunder by [Pinnacle]."

Reliances & Limitations

We have prepared this Report in conformity with its intended use by persons technically competent in the areas addressed and for the stated purposes only.

Throughout our analysis we have, without audit or verification, relied on historical data and qualitative information provided by NYS DFS, related agencies and MIF's services providers. The accuracy of our results is dependent upon the accuracy and completeness of this underlying data. Therefore, any material discrepancies discovered in this data or other information provided by NYS DFS, its related agencies or MIF's other service providers should be reported to us and this report amended accordingly.

This report includes graphs summarizing the Fund's raw data received for this and prior reports, information from the most recent fiscal year-end report at March 31, 2018, and summary information from similar funds in other states. In addition, we also reference the Fund's analysis as of March 31, 2017 reflecting the a priori estimates of the legislation signed into law on December 31, 2016. Review of these prior reports may provide further clarification of our comments and conclusions.

There is a limitation upon the accuracy of these estimates in that there is inherent uncertainty in any estimate of unpaid claims obligations and benefits. This is due to the fact that the ultimate liability for claims is subject to the outcome of events yet to occur, e.g., future program participant life expectancies, medical cost inflationary trends, etc. We have employed generally accepted actuarial techniques and assumptions that we believe are reasonable and appropriate. Further, the conclusions presented herein are reasonable and appropriate and supported by our analysis, given the information currently available. However, it should be recognized that future loss emergence will likely deviate, perhaps materially, from our estimates.

Additional uncertainty arises from lack of historical data and use of industry benchmarks. Our projections of future loss emergence and benefit payments are based primarily on aggregate insurance industry loss development patterns. It is possible that these patterns may not be indicative of future loss development for MIF.

Estimates discounted for the time value of money can be more uncertain than those on an undiscounted basis. In addition to the usual uncertainty in projecting unpaid claims obligations and benefits, discounted estimates are also influenced by:

- Variations in the timing of actual benefit payments versus the rate of payment assumed in discounting estimates to present value
- Variation in the actual investment yield on the assets underlying the liabilities versus the assumed interest rate used in discounting.

INDEX OF EXHIBITS

Exhibit	Description
1	Fund Payments by Benefits and Injury Categories
2	Projected Balance Sheets and Income Statements
3	Actual vs. Expected Participant Counts & Benefit Payments
4	Payments by Admittance Quarter
5	Projected Payments by Admittance Quarter – Nominal and Discounted
6	Estimated Ultimate Benefits Payments by Admittance Year
7	Participant Profile
8	Administrative Expense Summary

New York Department of Financial Services

Quarterly Analysis of New York Medical Indemnity Fund

As of September 30, 2018

Fund Payments by Benefits Category

Virginia Birth Fund Percent Benefit Category Percent of Total FY 17/18 FY 16/17 FY 15/16 FY 14/15 FY 13/14 FY 12/13 Benefit Category 2018Q3 2018Q2 Total of Total Medical Treatment 426,656 478,884 1,723,663 1,111,413 868,110 573,589 263,209 35,184 5,480,710 5 38% Hospital Based Care 9.12% Hospital/Physician 1.33% 437,007 242,847 2,612,112 1,885,043 2,092,358 1,673,039 300,325 42,922 9,285,653 Surgical Care 0 83% 158,562 56,102 244,859 113,032 146,685 101,149 18,896 2,190 841,475 **Nursing Care** 5,164,468 4,076,231 15,456,991 10,627,012 8,153,130 6,438,280 2,345,151 552,120 52,813,384 51.85% Nursing 66.05% Dental Care 0 22% 11,229 21,663 65,950 43,620 43,956 28,510 8,619 586 224,133 Rehabilitation Care 4 32% Physical Therapy 2.59% 268,964 209,136 1,032,868 1,135,719 995,410 630,482 62,821 60,191 4,395,592 **Custodial Care** 796,087 668,456 2,143,798 1,131,480 485,434 69,581 9,248 5,304,083 5 21% Durable Med Equip 688,081 519,337 1,788,009 945,751 880,138 533,009 416,785 42,169 5,813,279 5.71% Medical Equipment 1.76% Home Modifications 352,211 401,555 1,743,688 1.208.614 674,666 700,673 292,218 6.110 5.379.734 5 28% 11.09% Housing Vehicle Modifications 35,998 51,170 334,887 249,284 153,585 180,606 37,247 1,042,777 1 02% Vans 5.01% Prescription and Non-Prescriptive Drugs 510,289 696,922 2,900,007 2,537,792 1,669,450 872,352 281,662 65,176 9,533,651 9 36% Prescription Drugs 1.01% Other Health Care Costs 347,793 299,908 693,265 46,590 38,122 43,311 12,976 360 1,482,326 1.46% All Other 11.15% 11,269 0 01% Assistive Technology 616 500 1,244 13,629 Other Payments 46,876 37,207 83,211 64,014 14,022 7,404 (4) 252,738 0 25% 9,255,490 Total 7,759,418 30,823,926 21,099,865 16,216,310 11,851,988 4,049,151 807,015 101,863,163 100.00%

Notes

Fiscal years begin on April 1st; quarters shown are labeled by calendar year

FY 12/13 includes only 4th quarter 2012 and 1st quarter 2013; FY 12/13 does not include payments when Sedgwick was TPA Some payments made in 2017Q4 allocated to 2017Q3 to account for September claims payments

Exhibit 1

Page 1

New York Department of Financial Services

Quarterly Analysis of New York Medical Indemnity Fund

As of September 30, 2018

Fund Payments by Injury Category

									Total	Percent of	Number of	Percent of Total	Total Injury Category	Number of Participant	Injury Category Annualized
Injury Category	2018Q3	2018Q2	FY 17/18	FY 16/17	FY 15/16	FY 14/15	FY 13/14	FY 12/13	Payments	Total Payments	Participants	Participants	Severity	Quarters	Severity
Brachial Plexus	9,382	6,151	43,110	10,549	11,927	8,466	2,687	20	92,270	0.10%	26	4.60%	3,549	294	1,255
Erbs Palsy	43,887	25,607	95,773	32,885	34,007	25,640	3,617	27	261,416	0.28%	39	6.90%	6,703	537	1,947
Spastic Diplegia	20,398	25,448	113,869	58,214	65,865	53,702		25	337,496	0.36%	7	1.24%	48,214	124	10,887
Hemiplegia	59,502	18,269	67,331	86,939	18,250	52,271	53,464	4,331	360,356	0.38%	17	3.01%	21,197	264	5,460
Mental Retardation	90,026	96,834	576,004	433,236	514,888	176,580	32,714	14,964	1,935,247	2.05%	16	2.83%	120,953	257	30,121
Developmental Delays	529,331	409,184	1,507,988	1,251,998	1,265,010	949,237	152,790	389	6,065,926	6.43%	65	11.50%	93,322	984	24,658
Neurological Disabilities	1,053,168	958,169	3,097,854	1,788,924	1,130,909	571,830	169,875	17,260	8,787,989	9.31%	55	9.73%	159,782	808	43,505
Spastic Paraplegia	24,902	14,570	71,800	21,081	39,287	57,729	10000	27	229,368	0.24%	2	0.35%	114,684	25	36,699
Cerebral Palsy	2,459,409	1,757,839	8,018,968	5,909,418	4,116,581	3,052,208	1,227,845	212,024	26,754,291	28.34%	131	23.19%	204,231	1,912	55,971
Encephalopathy	2,148,382	1,924,770	6,400,545	4,109,928	3,785,684	3,244,944	1,055,853	209,787	22,879,894	24.24%	102	18.05%	224,313	1,517	60,329
Spastic Quadriplegia	1,761,878	1,401,531	5,917,532	3,839,667	2,999,106	2,096,547	675,214	45,764	18,737,240	19.85%	67	11.86%	279,660	846	88,592
Other	391,301	336,174	1,699,827	892,244	640,451	707,892	492,737	233,864	5,394,490	5.71%	28	4.96%	192,660	411	52,501
Quadriplegia	157,109	68,264	493,110	327,236	272,060	127,694	15	-1	1,445,473	1.53%	2	0.35%	722,736	27	214,144
Not Available	44,451	48,607	277,318	351,832	128,354	149,457	46,031	68,632	1,114,682	1.18%	8	1.42%	139,335	183	24,365
Total	8,793,125	7,091,416	28,381,030	19,114,151	15,022,378	11,274,197	3,912,827	807,015	94,396,139		565	100.00%	167,073	8,189	46,109

Notes

Fiscal years begin on April 1st; quarters shown are labeled by calendar year

Note: FY 12/13 includes only 4th quarter 2012 and 1st quarter 2013. MedCare invoices for prescriptions also excluded.

Total Injury Category Severity = Total Payments / Number of Participants

Total Injury Category Annualized Severity = Total Payments / Number of Participant Quarters x 4

Exhibit 1

Total

Page 2

Exhibit 2

Page 1

BALANCE SHEET

	Projections as of Fiscal Year-End										
	At 9/30/18	2018-19	2019-20	2020-21	2021-22	2022-23	2023-24	2024-25	2025-26	2026-27	2027-28
Assets											
Fund Balance	260,192.1	292,624.9	301,682.4	326,513.4	347,967.0	365,583.4	378,775.9	387,266.4	390,561.2	388,442.9	380,652.7
Liabilities											
Future Benefits for Current Participants	766,630.5	819,072.3	927,529.6	1,054,782.0	1,186,778.3	1,323,548.4	1,464,797.1	1,610,694.1	1,760,907.0	1,915,403.6	2,074,343.2
Future Administrative Expenses	116,436.2	127,461.5	148,137.3	169,559.4	191,791.0	214,846.8	238,702.9	263,361.3	288,766.1	314,917.3	333,678.3
Surplus/(Unfunded Liability)	(622,874.7)	(653,908.9)	(773,984.5)	(897,828.1)	(1,030,602.4)	(1,172,811.8)	(1,324,724.1)	(1,486,789.1)	(1,659,111.9)	(1,841,877.9)	(2,027,368.8)

INCOME STATEMENT

	At 9/30/18	2018-19*	2019-20	2020-21	2021-22	2022-23	2023-24	2024-25	2025-26	2026-27	2027-28
Initial Fund Balance		260,192.1	292,624.9	301,682.4	326,513.4	347,967.0	365,583.4	378,775.9	387,266.4	390,561.2	388,442.9
Annual Funding		52,000.0	52,000.0	52,000.0	52,000.0	52,000.0	52,000.0	52,000.0	52,000.0	52,000.0	52,000.0
Investment Income @ 2.50%		6,182.9	6,695.2	7,113.5	7,684.9	8,167.3	8,547.6	8,815.3	8,960.8	8,975.4	8,853.0
Benefit Payments		23,085.7	44,058.3	28,319.4	31,733.9	35,320.4	39,198.7	43,196.9	47,520.1	51,883.1	56,320.3
Administrative Expenses		2,664.4	5,579.4	5,963.2	6,497.4	7,230.5	8,156.5	9,128.0	10,145.9	11,210.6	12,323.0
Final Fund Balance	260,192.1	292,624.9	301,682.4	326,513.4	347,967.0	365,583.4	378,775.9	387,266.4	390,561.2	388,442.9	380,652.7
Change in Fund Balance		32,432.9	9,057.5	24,831.0	21,453.6	17,616.4	13,192.4	8,490.5	3,294.9	(2,118.3)	(7,790.2)
Benefit Payments as % of Initial Fund Balance		8.9%	15.1%	9.4%	9.7%	10.2%	10.7%	11.4%	12.3%	13.3%	14.5%
Number of Participants											
Initial		556	598	681	763	845	925	1,004	1,081	1,158	1,233
Expected New		46	92	92	93	93	93	93	93	92	92
Expected Deceased		4	9	10	11	13	14	15	16	17	18
Final	556	598	681	763	845	925	1,004	1,081	1,158	1,233	1,306
		*2018-19 amoun	ts on income state	ement reflect rema	ainder of fiscal year	r (from 9/30/18 th	rough 3/1/19)				

Notes

Balance Sheet - Assets Calculated in Income Statement

Balance Sheet - Liabilities Future Benefits from Exhibit 5, Pages 4-6 discounted to current evaluation

Future Expenses based on current administrative costs

Balance Sheet - Surplus = Assets - Liabilities

Income Statement - Initial Fund Balance = Final Fund Balance of prior period

Provided by MIF Income Statement - Annual Funding

Calculated based on 2.5% assumed investment return and assuming average date of benefit and expense payments is the middle of the fiscal period Income Statement - Investment Income

Income Statement - Benefit Payments From Exhibit 5, Pages 1-3

Income Statement - Admin Expenses Calculated based on current and projected participant counts and administrative expense contracts provided by MIF

Income Statement - Final Fund Balance = Initial Fund Balance + Annual Funding + Investment Income - Benefit Payments - Administrative Expenses

Income Statement - Change in Fund Balance = Final Fund Balance - Initial Fund Balance

Income Statement - Benefit Payments as %

of Initial Fund Balance = Benefit Payments / Initial Fund Balance

Initial from Exhibit 7 Income Statement - Number of Participants Expected New from Exhibit 3

Expected Deceased based on assumed 1.5% rate of deaths for current participants

Final = Initial + Expected New - Expected Deceased

Exhibit 2 Page 2

Quarterly Analysis of New York Medical Indemnity Fund

Future Fund Balances by Fiscal Year (000s) as of September 30, 2018

Undiscounted

BALANCE SHEET

					Project	tions as of Fiscal Y	ear-End				10
	At 9/30/18	2018-19	2019-20	2020-21	2021-22	2022-23	2023-24	2024-25	2025-26	2026-27	2027-28
<u>Assets</u> Fund Balance	260,192.1	286,442.0	288,804.3	306,521.8	320,290.4	329,739.6	334,384.4	334,059.5	328,393.6	317,299.9	300,656.7
<u>Liabilities</u> Future Benefits for Current Participants	1,964,231.3	2,138,995.4	2,506,544.6	2,908,919.4	3,340,437.6	3,802,829.9	4,296,327.5	4,823,500.3	5,385,014.9	5,982,158.8	6,616,949.9
Future Administrative Expenses	314,248.0	351,166.2	416,642.4	486,832.1	562,146.4	642,882.5	729,231.5	821,496.2	919,823.5	1,024,447.6	1,085,478.6
Surplus/(Unfunded Liability)	(2,018,287.2)	(2,203,719.6)	(2,634,382.7)	(3,089,229.7)	(3,582,293.5)	(4,115,972.8)	(4,691,174.6)	(5,310,937.0)	(5,976,444.8)	(6,689,306.42)	(7,401,771.81)

INCOME STATEMENT

-	At 9/30/18	2018-19	2019-20	2020-21	2021-22	2022-23	2023-24	2024-25	2025-26	2026-27	2027-28
Initial Fund Balance		260,192.1	286,442.0	288,804.3	306,521.8	320,290.4	329,739.6	334,384.4	334,059.5	328,393.6	317,299.9
Annual Funding		52,000.0	52,000.0	52,000.0	52,000.0	52,000.0	52,000.0	52,000.0	52,000.0	52,000.0	52,000.0
Benefit Payments		23,085.7	44,058.3	28,319.4	31,733.9	35,320.4	39,198.7	43,196.9	47,520.1	51,883.1	56,320.3
Administrative Expenses		2,664.4	5,579.4	5,963.2	6,497.4	7,230.5	8,156.5	9,128.0	10,145.9	11,210.6	12,323.0
Final Fund Balance*	260,192.1	286,442.0	288,804.3	306,521.8	320,290.4	329,739.6	334,384.4	334,059.5	328,393.6	317,299.9	300,656.7
Change in Fund Balance		26,249.9	2,362.3	17,717.4	13,768.7	9,449.2	4,644.8	(324.8)	(5,666.0)	(11,093.7)	(16,643.3)
Benefit Payments as % of Initial Fund Balance		8.9%	15.4%	9.8%	10.4%	11.0%	11.9%	12.9%	14.2%	15.8%	17.7%
Number of Participants											
Initial		556	598	681	763	845	925	1,004	1,081	1,158	1,233
Expected New		46	92	92	93	93	93	93	93	92	92
Expected Deceased		4	9	10	11	13	14	15	16	17	18
Final	556	598	681	763	845	925	1,004	1,081	1,158	1,233	1,306
		*2018-19 amoun	ts on income state	ment reflect rema	inder of fiscal year	(from 9/30/18 th	rough 3/1/19)				

Notes

Balance Sheet - Assets Calculated in Income Statement

Balance Sheet - Liabilities Future Benefits from Exhibit 5, Pages 1-3 discounted to current evaluation

Future Expenses based on current administrative costs

Balance Sheet - Surplus = Assets - Liabilities

Income Statement - Initial Fund Balance = Final Fund Balance of prior period

Income Statement - Annual Funding Provided by MIF Income Statement - Benefit Payments From Exhibit 5, Pages 1-3

Income Statement - Admin Expenses Calculated based on current and projected participant counts and administrative expense contracts provided by MIF

Income Statement - Final Fund Balance = Initial Fund Balance + Annual Funding - Benefit Payments - Administrative Expenses

Income Statement - Change in Fund Balance = Final Fund Balance - Initial Fund Balance

Income Statement - Benefit Payments as %

of Initial Fund Balance = Benefit Payments / Initial Fund Balance

Income Statement - Number of Participants Initial from Exhibit 7

Expected New from Exhibit 3

Expected Deceased based on assumed 1.5% rate of deaths for current participants

Final = Initial + Expected New - Expected Deceased

New York Department of Financial Services

Quarterly Analysis of New York Medical Indemnity Fund

As of September 30, 2018

Actual vs. Expected Participant Counts & Benefit Payments

Fiscal	N	lew Participants	ic av x	To	otal Participants		Incremental Benefit Payments				
Period (1)	Actual (2a)	Expected (2b)	Difference (2c)	Actual (3a)	Expected (3b)	Difference (3c)	Actual (4a)	Revised Expected (4b)	Prior Expected (4c)	Difference (4d)	
Fiscal 2011-12 Total	22.00	22.00	(S)	22.00	22.00		3,146	3,146	3,146	0	
Fiscal 2012-13 Total	86.00	86.00	350	108.00	108.00	227	1,317,450	1,317,450	1,317,450	0	
Fiscal 2013-14 Total	84.00	84.00	923	192.00	192.00	20	4,049,151	4,049,151	4,049,151	0	
Fiscal 2014-15 Total	91.00	91.00	941	283.00	283.00	3±50	11,851,988	11,851,988	11,851,988	0	
Fiscal 2015-16 Total	85.00	85,00	((a))	368.00	368.00	960	16,216,310	16,216,310	16,216,310	0	
Fiscal 2016-17 Total	91.00	91.00	8554	459.00	459.00	1 = N	21,099,865	21,099,865	21,099,865	0	
Fiscal 2017-18 Total to Date	72.00	72.00	8,53	531.00	531.00	50	30,823,926	30,823,926	30,823,926	0	
2nd Qtr 2018	15.00	23.00	8.00	546.00	554.00	8.00	7,759,418	7,759,418	7,759,418	0	
3rd Qtr 2018	19.00	23.00	4.00	565.00	577.01	12.01	9,255,490	9,255,490	11,015,974	1,760,485	
4th Qtr 2018	1840	23.00	(=)	120	600.01	5 5 35	0	11,350,277	11,468,616	118,340	
1st Qtr 2019	850	23.00	1000) 5 0	623.02	18 0	0	11,735,379	11,848,491	113,112	
Fiscal 2018-19 Total	7 2	92.02	(2)	N 2 G	623.02	188	17,014,908	40,100,563	42,092,499	1,991,936	
Fiscal 2019-20 Total	970	92.33	3 5 6		715.35	1 4 %					
Fiscal 2020-21 Total	1576	92.41	85	55	807.76	50					
Fiscal 2021-22 Total	320	92.65	250	27	900.41	223					
Fiscal 2022-23 Total	12	92.83	(42)	227	993.25	20					
Fiscal 2023-24 Total	620	92.82	941	144	1,086.07	3200					
Fiscal 2024-25 Total	19 4 3	92.81	2 9 2	1 2 61	1,178.88	980					
Fiscal 2025-26 Total	8-9	92.62	(=)	180	1,271.50						
Fiscal 2026-27 Total	123	92.28	873	55	1,363.78	5.0					
Fiscal 2027-28 Total	674	91.93	# 5 :	27	1,455.72	17 55					

Notes

(2a), (3a), (4a)	Provided by Fund
(2b), (3b)	Based on Pinnacle estimates of future Fund participation rates
(2c), (3c)	Part (b) - Part (a) for both sections respectively
(4b)	Expected future benefit payments as of the current analysis
(4c)	Expected future benefit payments as of the prior analysis
(4d)	(4c) - (4b)

New York Department of Financial Services Quarterly Analysis of New York Medical Indemnity Fund Incremental Average Payments per Participant by Admittance Quarter As of September 30, 2018

Exhibit 4

Page 1

Admittance	Living	Incremental Severity per Participant by Participation Quarter															
Quarter	<u>Participants</u>	<u>Q1</u>	<u>Q2</u>	<u>Q3</u>	<u>Q4</u>	Q5	<u>Q6</u>	<u>Q7</u>	<u>Q8</u>	<u>Q9</u>	Q10	<u>Q11</u>	Q12	Q13	Q14	Q15	Q16
2011Q4	11	*	286	8,569	13,107	2,539	3,833	2,065	9,226	6,332	2,670	2,621	4,983	4,330	2,506	4,435	9,878
2012Q1	11	£	1,083	2,565	1,404	346	843	2,267	2,670	4,095	5,922	3,055	3,532	2,065	1,604	1,728	4,323
2012Q2	15	48	14,263	14,845	14,404	14,717	14,627	18,964	19,142	24,056	22,503	20,705	18,966	21,919	24,649	23,694	21,532
2012Q3	25	689	2,356	4,779	4,710	6,430	5,920	8,449	12,018	17,357	11,480	13,978	10,705	12,099	9,180	9,068	10,248
2012Q4	38	10	1,989	3,851	11,363	16,419	13,708	27,508	31,066	30,676	30,232	32,077	23,539	25,744	24,417	35,645	30,901
2013Q1	5	2	156	2,171	7,343	7,418	17,277	35,542	32,511	26,405	27,378	23,864	23,499	17,529	24,984	29,815	22,185
2013Q2	30	9	1,380	2,257	2,615	3,646	5,367	7,258	6,056	3,874	4,505	6,573	8,547	5,567	9,125	7,187	6,376
2013Q3	26	-	361	3,449	6,787	13,399	14,088	15,667	16,587	13,919	14,093	11,991	10,411	13,096	11,666	10,831	12,529
2013Q4	8	8	1,973	2,805	6,501	6,885	4,744	19,051	5,278	5,161	8,548	15,033	13,236	5,734	9,212	12,455	9,399
2014Q1	17	35	2,325	5,898	9,823	8,440	15,862	16,623	21,908	13,381	23,766	19,518	21,438	21,409	32,354	25,694	24,963
2014Q2	25	1,238	5,308	8,218	9,212	13,432	8,895	14,015	11,214	10,894	13,081	10,187	10,614	18,633	9,634	8,239	14,718
2014Q3	20	1,223	5,283	32,222	19,624	14,143	15,262	14,838	12,484	18,900	13,228	17,583	21,358	23,018	18,518	39,158	8,734
2014Q4	19	85	3,861	5,473	9,093	10,454	8,379	10,208	13,406	13,903	17,699	18,721	17,596	19,088	17,776	12,856	18,281
2015Q1	26	150	4,576	5,271	7,082	7,514	8,872	11,081	8,182	13,644	13,039	8,441	24,330	14,022	9,568	14,247	
2015Q2	31	4,421	12,991	14,039	11,387	13,234	16,886	12,313	21,351	19,941	14,838	14,716	26,627	17,721	25,509		
2015Q3	16	0.00	1,885	6,469	5,035	4,362	5,735	4,299	13,939	10,981	18,601	16,212	15,286	23,839			
2015Q4	20	191	5,104	4,559	8,601	16,067	10,555	12,617	9,035	7,292	14,114	15,850	15,341				
2016Q1	18	12	931	10,298	9,142	9,815	12,341	14,723	8,422	13,953	7,506	13,385					
2016Q2	35	290	2,039	4,599	7,550	5,772	11,891	7,051	15,321	23,381	19,189						
2016Q3	22		4,303	9,321	8,150	9,762	7,706	8,976	7,065	9,392							
2016Q4	14	3	11,232	11,240	18,161	12,826	23,382	11,326	27,431								
2017Q1	19	-	6,444	9,167	24,862	12,653	17,038	10,317									
2017Q2	28	340	5,987	6,603	13,511	11,404	15,585										
2017Q3	17	44	1,820	5,189	10,466	10,661											
2017Q4	11	83	1,217	24,666	21,320												
2018Q1	15	5.	114	5,951													
2018Q2	15		1,768														
2018Q3	19	5															
Total	556																

Note: 3rd Qtr 2017 diagonal data adjusted to account for no payments made in September

New York Department of Financial Services

Quarterly Analysis of New York Medical Indemnity Fund

Incremental Average Payments per Participant by Admittance Quarter

As of September 30, 2018

Admittance	Living	Incremental Severity per Participant by Participation Quarter													
Quarter	<u>Participants</u>	Q17	Q18	Q19	Q20	Q21	Q22	Q23	Q24	Q25	Q26	Q27	Q28		
2011Q4	11	4,680	2,614	4,516	4,553	5,070	5,433	6,349	5,433	5,168	13,122	9,719	8,937		
2012Q1	11	732	753	1,306	3,692	5,932	9,553	12,852	2,766	14,592	55,240	3,844			
2012Q2	15	25,875	23,286	22,464	25,066	29,353	28,463	23,256	47,581	34,446	29,018				
2012Q3	25	12,872	12,306	9,536	12,574	15,561	10,479	20,311	16,598	13,262					
2012Q4	38	23,856	27,316	46,825	40,156	20,090	40,543	20,434	45,752						
2013Q1	5	26,411	31,833	35,052	26,082	32,230	44,378	20,788							
2013Q2	30	9,517	8,214	4,678	12,809	8,178	9,627								
2013Q3	26	5,000	8,989	5,455	4,491	6,246									
2013Q4	8	11,548	11,407	13,560	6,748										
2014Q1	17	27,121	16,497	25,539											
2014Q2	25	8,951	12,525												
2014Q3	20	19,460	16/16/10/64												
2014Q4	19														
2015Q1	26														
2015Q2	31														
2015Q3	16														
2015Q4	20														
2016Q1	18														
2016Q2	35														
2016Q3	22														
2016Q4	14														
2017Q1	19														
2017Q2	28														
2017Q3	17														
2017Q4	11														
2018Q1	15														
2018Q2	15														
2018Q3	19														
Total	556														

Note: 3rd Qtr 2017 diagonal data adjusted to account for no payments made in September

Exhibit 4

Page 2

Exhibit 4

Page 3

Admittance	Living	Cumulative Severity by Fund Participation Quarter															
Quarter	<u>Participants</u>	<u>Q1</u>	Q2	Q3	Q4	Q5	<u>Q6</u>	Q7	Q8	Q9	Q10	Q11	Q12	Q13	Q14	Q15	Q16
2011Q4	11	=	286	8,855	21,962	24,500	28,334	30,399	39,625	45,957	48,628	51,248	56,231	60,561	63,067	67,501	77,380
2012Q1	11	12	1,083	3,648	5,052	5,397	6,240	8,508	11,177	15,273	21,195	24,251	27,783	29,848	31,451	33,179	37,502
2012Q2	15	48	14,310	29,155	43,560	58,277	72,904	91,867	111,009	135,065	157,568	178,273	197,239	219,159	243,808	267,502	289,033
2012Q3	25	689	3,045	7,823	12,534	18,964	24,884	33,333	45,351	62,708	74,188	88,166	98,871	110,970	120,150	129,218	139,466
2012Q4	38	10	1,999	5,850	17,213	33,633	47,340	74,848	105,914	136,589	166,821	198,898	222,437	248,181	272,599	308,244	339,144
2013Q1	5	=	156	2,327	9,670	17,088	34,365	69,907	102,417	128,822	156,200	180,064	203,563	221,092	246,076	275,891	298,075
2013Q2	30	3	1,380	3,637	6,252	9,897	15,265	22,523	28,579	32,452	36,957	43,531	52,078	57,645	66,770	73,957	80,334
2013Q3	26	-	361	3,810	10,597	23,996	38,084	53,751	70,338	84,257	98,350	110,341	120,752	133,848	145,514	156,345	168,874
2013Q4	8	8	1,981	4,786	11,287	18,173	22,917	41,967	47,246	52,406	60,955	75,988	89,224	94,958	104,169	116,624	126,024
2014Q1	17	35	2,361	8,258	18,081	26,521	42,383	59,006	80,914	94,295	118,062	137,580	159,018	180,427	212,781	238,475	263,437
201402	25	1,238	6,546	14,764	23,975	37,407	46,303	60,317	71,531	82,425	95,506	105,693	116,307	134,940	144,573	152,813	167,530
2014Q3	20	1,223	6,506	38,728	58,353	72,496	87,758	102,596	115,080	133,980	147,207	164,791	186,149	209,167	227,684	266,843	275,576
2014Q4	19	85	3,945	9,418	18,511	28,965	37,344	47,552	60,958	74,861	92,560	111,281	128,877	147,965	165,741	178,597	196,878
2015Q1	26	150	4,726	9,997	17,079	24,593	33,465	44,546	52,728	66,372	79,412	87,853	112,183	126,205	135,772	150,019	
2015Q2	31	4,421	17,412	31,452	42,839	56,073	72,958	85,272	106,623	126,564	141,401	156,117	182,744	200,466	225,975		
2015Q3	16	200	1,885	8,354	13,389	17,751	23,486	27,785	41,724	52,705	71,305	87,517	102,803	126,643			
2015Q4	20	191	5,296	9,855	18,456	34,523	45,078	57,695	66,731	74,023	88,137	103,987	119,328				
2016Q1	18	12	942	11,240	20,382	30,198	42,538	57,262	65,684	79,637	87,143	100,527					
2016Q2	35	290	2,329	6,928	14,477	20,249	32,140	39,191	54,512	77,893	97,081						
2016Q3	22	-	4,303	13,624	21,774	31,536	39,242	48,218	55,283	64,676							
2016Q4	14	9	11,232	22,473	40,633	53,460	76,841	88,167	115,599								
2017Q1	19		6,444	15,611	40,473	53,126	70,164	80,481	economic orders								
2017Q2	28	340	6,326	12,929	26,440	37,843	53,429										
2017Q3	17	44	1,864	7,053	17,520	28,181	102										
2017Q4	11	83	1,299	25,965	47,285												
2018Q1	15	201	114	6,065	THE STATE OF THE STATE OF												
2018Q2	15	-	1,768	97,57,77,77													
2018Q3	19	ie.															
Total	556																

Note: 3rd Qtr 2017 diagonal data adjusted to account for no payments made in September

New York Department of Financial Services Quarterly Analysis of New York Medical Indemnity Fund Cumulative Average Payments per Participant by Admittance Quarter As of September 30, 2018

Exhibit 4

Page 4

	36												
Admittance	Living												
Quarter	<u>Participants</u>	Q17	Q18	Q19	Q20	Q21	Q22	Q23	Q24	Q25	Q26	Q27	Q28
2011Q4	11	82,060	84,674	89,190	93,743	98,814	104,246	110,595	116,028	121,196	134,317	144,037	
2012Q1	11	38,234	38,987	40,293	43,985	49,917	59,470	72,322	75,087	89,679	144,919	148,763	
2012Q2	15	314,908	338,195	360,658	385,724	415,077	443,540	466,797	514,378	548,823	577,841		
2012Q3	25	152,339	164,644	174,180	186,754	202,315	212,794	233,104	249,702	262,964			
2012Q4	38	363,000	390,316	437,141	477,297	497,387	537,930	558,364	604,116				
2013Q1	5	324,486	356,319	391,371	417,453	449,684	494,062	514,849					
2013Q2	30	89,851	98,064	102,742	115,552	123,729	133,356						
2013Q3	26	173,874	182,862	188,317	192,809	199,054							
2013Q4	8	137,572	148,979	162,539	169,287								
2014Q1	17	290,558	307,055	332,594									
2014Q2	25	176,481	189,006										
2014Q3	20	295,036											
2014Q4	19												
2015Q1	26												
2015Q2	31												

Note: 3rd Qtr 2017 diagonal data adjusted to account for no payments made in September

2015Q3

2015Q4

2016Q1

2016Q2

2016Q3

2016Q4

2017Q1

2017Q2

2017Q3

2017Q4

2018Q1

2018Q2 2018Q3

Total

16

20

18

35

22

14

19

28

17

11

15 15

19 556

Exhibit 4

Page 5

Admittance	Living							Incremental I	Benefits Paid	by Fund Partic	ipation Quar	ter					
Quarter	<u>Participants</u>	<u>Q1</u>	<u>Q2</u>	<u>Q3</u>	Q4	Q5	<u>Q6</u>	<u>Q7</u>	<u>Q8</u>	Q9	Q10	Q11	Q12	Q13	Q14	Q15	Q16
2011Q4	11	#1	3,146	94,260	144,173	27,926	42,167	22,720	101,483	69,656	29,373	28,827	54,812	47,626	27,564	48,782	108,661
2012Q1	11	*	11,909	28,215	15,444	3,802	9,275	24,942	29,365	45,050	65,147	33,607	38,857	22,710	17,639	19,004	47,555
2012Q2	15	717	213,939	222,675	216,063	220,760	219,402	284,456	287,128	360,835	337,540	310,577	284,497	328,790	369,738	355,414	322,973
2012Q3	25	17,222	58,895	119,468	117,755	160,748	148,012	211,218	300,445	433,929	286,997	349,458	267,625	302,467	229,506	226,706	256,203
2012Q4	38	371	75,588	146,333	431,812	623,934	520,889	1,045,294	1,180,508	1,165,671	1,148,800	1,218,933	894,490	978,263	927,857	1,354,514	1,174,223
2013Q1	5	70	780	10,857	36,713	37,090	86,384	177,708	162,554	132,023	136,890	119,318	117,497	87,645	124,918	149,075	110,923
2013Q2	30	58	41,406	67,708	78,441	109,369	161,013	217,746	181,675	116,207	135,157	197,202	256,410	167,023	273,743	215,624	191,285
2013Q3	26	Steen	9,394	89,664	176,462	348,379	366,278	407,351	431,269	361,886	366,426	311,761	270,692	340,485	303,320	281,603	325,761
2013Q4	8	60	15,787	22,442	52,010	55,080	37,953	152,406	42,227	41,285	68,386	120,264	105,891	45,872	73,694	99,640	75,194
2014Q1	17	602	39,529	100,258	166,996	143,474	269,659	282,592	372,432	227,482	404,028	331,801	364,447	363,952	550,020	436,798	424,367
2014Q2	25	30,945	132,707	205,442	230,289	335,796	222,383	350,374	280,346	272,353	327,022	254,665	265,346	465,824	240,840	205,985	367,940
2014Q3	20	24,460	105,657	644,449	392,488	282,863	305,247	296,763	249,677	377,991	264,554	351,669	427,155	460,362	370,354	783,163	174,676
2014Q4	19	1,609	73,351	103,984	172,768	198,623	159,203	193,955	254,713	264,161	336,275	355,696	334,321	362,678	337,740	244,266	347,343
2015Q1	26	3,902	118,971	137,048	184,125	195,370	230,680	288,099	212,728	354,753	339,026	219,468	632,582	364,574	248,757	370,420	
2015Q2	31	137,049	402,726	435,224	352,996	410,257	523,451	381,714	661,892	618,164	459,971	456,194	825,441	549,361	790,790		
2015Q3	16	Ħ8	30,164	103,507	80,558	69,794	91,758	68,778	223,018	175,695	297,615	259,387	244,576	381,432			
2015Q4	20	3,829	102,088	91,181	172,019	321,337	211,106	252,349	180,709	145,837	282,289	316,999	306,819				
2016Q1	18	210	16,754	185,361	164,559	176,678	222,131	265,022	151,593	251,157	135,105	240,923					
2016Q2	35	10,141	71,367	160,956	264,242	202,010	416,172	246,795	536,249	818,321	671,599						
2016Q3	22	2:	94,668	205,067	179,295	214,771	169,535	197,464	155,428	206,635							
2016Q4	14	50	157,250	157,366	254,248	179,571	327,343	158,566	384,037								
2017Q1	19	5	122,431	174,172	472,382	240,410	323,718	196,024									
2017Q2	28	9,506	167,627	184,879	378,303	319,302	436,388										
2017Q3	17	750	30,939	88,216	177,929	181,238											
2017Q4	11	910	13,384	271,321	234,524												
2018Q1	15	2,	1,706	89,268													
2018Q2	15	26	26,518														
2018Q3	19	<u> </u>															
Total	556																

Note: 3rd Qtr 2017 diagonal data adjusted to account for no payments made in September

New York Department of Financial Services Quarterly Analysis of New York Medical Indemnity Fund Incremental Benefits Payments by Admittance Quarter As of September 30, 2018

Exhibit 4

Page 6

Admittance	Living					ncremental I	Benefits Paid b	y Fund Partic	ipation Quarte	er				
Quarter	<u>Participants</u>	Q17	Q18	Q19	Q20	Q21	Q22	Q23	Q24	Q25	Q26	Q27	Q28	<u>Total</u>
2011Q4	11	51,481	28,752	49,678	50,087	55,775	59,762	69,834	59,758	56,849	144,337	106,913	98,308	1,682,712
2012Q1	11	8,050	8,287	14,368	40,610	65,249	105,081	141,372	30,423	160,512	607,638	42,285		1,636,396
2012Q2	15	388,125	349,296	336,954	375,984	440,301	426,941	348,845	713,715	516,684	435,265			8,667,612
2012Q3	25	321,808	307,643	238,399	314,347	389,016	261,971	507,772	414,951	331,539				6,574,100
2012Q4	38	906,524	1,038,009	1,779,355	1,525,926	763,402	1,540,636	776,503	1,738,563					22,956,397
2013Q1	5	132,056	159,165	175,258	130,412	161,152	221,890	103,938						2,574,247
2013Q2	30	285,507	246,411	140,344	384,275	245,332	288,796							4,000,673
2013Q3	26	129,991	233,702	141,831	116,773	162,384								5,175,413
2013Q4	8	92,384	91,257	108,478	53,984									1,354,293
2014Q1	17	461,052	280,450	434,155										5,654,094
2014Q2	25	223,774	313,120											4,725,152
2014Q3	20	389,194												5,900,724
2014Q4	19													3,740,687
2015Q1	26													3,900,504
2015Q2	31													7,005,230
2015Q3	16													2,026,282
2015Q4	20													2,386,561
2016Q1	18													1,809,493
2016Q2	35													3,397,852
2016Q3	22													1,422,862
2016Q4	14													1,618,380
2017Q1	19													1,529,136
2017Q2	28													1,496,005
2017Q3	17													479,072
2017Q4	11													520,139
2018Q1	15													90,975
2018Q2	15													26,518
2018Q3	19													
Total	556													102,351,512
Total	330													102,001,012

Admittance	Living							Cumulativ	e Benefits by	Fund Participa	ation Quarter						
Quarter	<u>Participants</u>	<u>Q1</u>	Q2	<u>Q3</u>	<u>Q4</u>	<u>Q5</u>	<u>Q6</u>	Q7	<u>Q8</u>	<u>Q9</u>	Q10	Q11	Q12	Q13	Q14	Q15	Q16
2011Q4	11	£61	3,146	97,406	241,579	269,505	311,672	334,391	435,875	505,531	534,904	563,731	618,543	666,169	693,733	742,515	851,176
2012Q1	11	1983	11,909	40,124	55,568	59,370	68,645	93,587	122,952	168,002	233,149	266,756	305,613	328,323	345,962	364,966	412,521
2012Q2	15	717	214,656	437,331	653,394	874,153	1,093,555	1,378,011	1,665,139	2,025,974	2,363,513	2,674,090	2,958,587	3,287,378	3,657,115	4,012,529	4,335,502
2012Q3	25	17,222	76,117	195,585	313,341	474,089	622,100	833,319	1,133,763	1,567,693	1,854,690	2,204,148	2,471,773	2,774,240	3,003,745	3,230,451	3,486,654
2012Q4	38	371	75,958	222,292	654,104	1,278,038	1,798,927	2,844,220	4,024,728	5,190,399	6,339,199	7,558,133	8,452,623	9,430,886	10,358,743	11,713,258	12,887,481
2013Q1	5	950	780	11,637	48,351	85,440	171,825	349,533	512,087	644,110	781,000	900,318	1,017,815	1,105,460	1,230,378	1,379,453	1,490,376
2013Q2	30	105	41,406	109,114	187,555	296,924	457,936	675,682	857,357	973,565	1,108,721	1,305,923	1,562,333	1,729,356	2,003,100	2,218,724	2,410,008
2013Q3	26	2. - 9	9,394	99,058	275,521	623,900	990,178	1,397,528	1,828,797	2,190,683	2,557,109	2,868,870	3,139,562	3,480,047	3,783,367	4,064,970	4,390,731
2013Q4	8	60	15,848	38,290	90,300	145,380	183,334	335,739	377,966	419,251	487,637	607,900	713,791	759,662	833,356	932,996	1,008,190
2014Q1	17	602	40,131	140,389	307,385	450,858	720,517	1,003,109	1,375,541	1,603,023	2,007,051	2,338,852	2,703,299	3,067,251	3,617,271	4,054,069	4,478,436
2014Q2	25	30,945	163,652	369,094	599,383	935,179	1,157,563	1,507,937	1,788,283	2,060,636	2,387,658	2,642,323	2,907,669	3,373,493	3,614,333	3,820,318	4,188,258
2014Q3	20	24,460	130,117	774,566	1,167,055	1,449,918	1,755,165	2,051,928	2,301,605	2,679,596	2,944,150	3,295,818	3,722,974	4,183,336	4,553,690	5,336,853	5,511,529
2014Q4	19	1,609	74,960	178,944	351,712	550,336	709,539	903,494	1,158,207	1,422,368	1,758,643	2,114,339	2,448,660	2,811,338	3,149,078	3,393,344	3,740,687
2015Q1	26	3,902	122,872	259,920	444,045	639,416	870,096	1,158,195	1,370,923	1,725,676	2,064,703	2,284,171	2,916,752	3,281,327	3,530,084	3,900,504	
2015Q2	31	137,049	539,776	974,999	1,327,995	1,738,252	2,261,703	2,643,417	3,305,309	3,923,472	4,383,444	4,839,638	5,665,079	6,214,440	7,005,230		
2015Q3	16	25-2	30,164	133,672	214,230	284,024	375,782	444,559	667,577	843,272	1,140,887	1,400,274	1,644,850	2,026,282			
2015Q4	20	3,829	105,918	197,098	369,117	690,453	901,560	1,153,908	1,334,617	1,480,454	1,762,744	2,079,742	2,386,561				
2016Q1	18	210	16,964	202,325	366,884	543,562	765,693	1,030,715	1,182,308	1,433,465	1,568,570	1,809,493					
2016Q2	35	10,141	81,508	242,464	506,706	708,716	1,124,888	1,371,684	1,907,933	2,726,253	3,397,852						
2016Q3	22	320	94,668	299,734	479,029	693,799	863,335	1,060,799	1,216,227	1,422,862							
2016Q4	14	953	157,250	314,616	568,864	748,435	1,075,778	1,234,343	1,618,380								
2017Q1	19	1071	122,431	296,602	768,985	1,009,395	1,333,113	1,529,136									
2017Q2	28	9,506	177,133	362,013	740,316	1,059,618	1,496,005										
2017Q3	17	750	31,689	119,904	297,834	479,072											

Note: 3rd Qtr 2017 diagonal data adjusted to account for no payments made in September

14,294

1,706

26,518

285,615

90,975

520,139

910

2017Q4

2018Q1

201802

2018Q3

Total

11

15

15

19

556

New York Department of Financial Services Quarterly Analysis of New York Medical Indemnity Fund Cumulative Benefits Payments by Admittance Quarter As of September 30, 2018

Exhibit 4 Page 8

Admittance	Living					Cumulativ	e Benefits by	Fund Particip	ation Quarter					
Quarter	<u>Participants</u>	Q17	Q18	Q19	Q20	Q21	Q22	Q23	Q24	Q25	Q26	Q27	Q28	Total
2011Q4	11	902,658	931,410	981,088	1,031,175	1,086,949	1,146,711	1,216,546	1,276,304	1,333,154	1,477,490	1,584,403	1,682,712	1,682,712
2012Q1	11	420,571	428,858	443,225	483,835	549,084	654,165	795,538	825,961	986,473	1,594,111	1,636,396		1,636,396
2012Q2	15	4,723,627	5,072,924	5,409,877	5,785,861	6,226,162	6,653,103	7,001,948	7,715,663	8,232,347	8,667,612			8,667,612
2012Q3	25	3,808,463	4,116,105	4,354,505	4,668,852	5,057,868	5,319,839	5,827,611	6,242,562	6,574,100				6,574,100
2012Q4	38	13,794,005	14,832,013	16,611,368	18,137,294	18,900,696	20,441,331	21,217,834	22,956,397					22,956,397
2013Q1	5	1,622,432	1,781,597	1,956,855	2,087,267	2,248,419	2,470,309	2,574,247						2,574,247
2013Q2	30	2,695,515	2,941,926	3,082,271	3,466,545	3,711,877	4,000,673							4,000,673
2013Q3	26	4,520,722	4,754,424	4,896,255	5,013,028	5,175,413								5,175,413
2013Q4	8	1,100,574	1,191,831	1,300,310	1,354,293									1,354,293
2014Q1	17	4,939,488	5,219,939	5,654,094										5,654,094
2014Q2	25	4,412,032	4,725,152											4,725,152
2014Q3	20	5,900,724												5,900,724
2014Q4	19													3,740,687
2015Q1	26													3,900,504
2015Q2	31													7,005,230
2015Q3	16													2,026,282
2015Q4	20													2,386,561
2016Q1	18													1,809,493
2016Q2	35													3,397,852
2016Q3	22													1,422,862
2016Q4	14													1,618,380
2017Q1	19													1,529,136
201702	28													1,496,005
2017Q3	17													479,072
2017Q4	11													520,139
2018Q1	15													90,975
2018Q2	15													26,518
2018Q3	19													12
Total	556													102,351,512

Note: 3rd Qtr 2017 diagonal data adjusted to account for no payments made in September

New York Department of Financial Services Quarterly Analysis of New York Medical Indemnity Fund

Page 1 Projected Incremental Nominal Payments per Participant by Admittance Quarter

dmittance											Increme	stal Benefits P	aid by Fund F	articipation	Quarter										
Quarter	Participants	01	02	<u>Q3</u>	Q4	Q5	Q6	Q7	Q8	Q9	Q10	011	Q12	Q13	Q14	Q15	016	Q17	Q18	Q19	Q20	Q21	Q22	Q23	Q24
2011Q4	11	100	3 146	94 260	144 173	27 926	42 167	22 720	101 483	69 656	29 373	28 827	54 812	47 626	27 564	48 782	108 661	51 481	28 752	49 678	50 087	55 775	59 762	69 834	59 758
2012Q1	11	-	11 909	28 215	15 444	3 802	9 275	24 942	29 365	45 050	65 147	33 607	38 857	22 710	17 639	19 004	47 555	8 050	8 287	14 368	40 610	65 249	105 081	141 372	30 423
201202	15	717	213 939	222 675	216 063	220 760	219 402	284 456	287 128	360 835	337 540	310 577	284 497	328 790	369 738	355 414	322 973	388 125	349 296	336 954	375 984	440 301	426 941	348 845	713 719
2012Q3	25	17 222	58 895	119 468	117 755	160 748	148 012	211 218	300 445	433 929	286 997	349 458	267 625	302 467	229 506	226 706	256 203	321 808	307 643	238 399	314 347	389 016	261 971	507 772	414 951
2012Q4	38	371	75 588	146 333	431 812	623 934	520 889	1 045 294	1 180 508	1 165 671	1 148 800	1 218 933	894 490	978 263	927 857	1 354 514	1 174 223	906 524	1 038 009	1 779 355	1 525 926	763 402	1 540 636	776 503	1 738 563
201301	5	12	780	10 857	36 713	37 090	86 384	177 708	162 554	132 023	136 890	119 318	117 497	87 645	124 918	149 075	110 923	132 056	159 165	175 258	130 412	161 152	221 890	103 938	138 290
201302	30	9.7	41 406	67 708	78 441	109 369	161 013	217 746	181 675	116 207	135 157	197 202	256 410	167 023	273 743	215 624	191 285	285 507	246 411	140 344	384 275	245 332	288 796	227 709	227 709
2013Q3	26	89	9 394	89 664	176 462	348 379	366 278	407 351	431 269	361 886	366 426	311 761	270 692	340 485	303 320	281 603	325 761	129 991	233 702	141 831	116 773	162 384	329 532	329 532	329 532
2013Q4	8	60	15 787	22 442	52 010	55 080	37 953	152 406	42 227	41 285	68 386	120 264	105 891	45 872	73 694	99 640	75 194	92 384	91 257	108 478	53 984	89 314	89 314	89 314	89 314
2014Q1	17	602	39 529	100 258	166 996	143 474	269 659	282 592	372 432	227 482	404 028	331 801	364 447	363 952	550 020	436 798	424 367	461 052	280 450	434 155	425 316	336 443	336 443	336 443	336 443
201402	25	30 945	132 707	205 442	230 289	335 796	222 383	350 374	280 346	272 353	327 022	254 665	265 346	465 824	240 840	205 985	367 940	223 774	313 120	472 855	472 855	374 049	374 049	374 049	187 025
201403	20	24 460	105 657	644 449	392 488	282 863	305 247	296 763	249 677	377 991	264 554	351 669	427 155	460 362	370 354	783 163	174 676	389 194	565 278	565 278	565 278	447 159	447 159	223 580	223 580
2014Q4	19	1 609	73 351	103 984	172 768	198 623	159 203	193 955	254 713	264 161	336 275	355 696	334 321	362 678	337 740	244 266	347 343	352 580	352 580	352 580	352 580	278 906	139 453	139 453	139 453
201501	26	3 902	118 971	137 048	184 125	195 370	230 680	288 099	212 728	354 753	339 026	219 468	632 582	364 574	248 757	370 420	378 700	363 744	363 744	363 744	363 744	143 869	143 869	143 869	143 869
2015Q2	31	137 049	402 726	435 224	352 996	410 257	523 451	381 714	661 892	618 164	459 971	456 194	825 441	549 361	790 790	798 974	798 974	767 421	767 421	767 421	383 710	303 532	303 532	303 532	303 532
2015Q3	16	-	30 164	103 507	80 558	69 794	91 758	68 778	223 018	175 695	297 615	259 387	244 576	381 432	156 724	156 724	156 724	150 535	150 535	75 267	75 267	59 540	59 540	59 540	59 540
2015Q4	20	3 829	102 088	91 181	172 019	321 337	211 106	252 349	180 709	145 837	282 289	316 999	306 819	325 021	325 021	325 021	325 021	312 185	156 092	156 092	156 092	123 476	123 476	123 476	123 476
2016Q1	18	210	16 754	185 361	164 559	176 678	222 131	265 022	151 593	251 157	135 105	240 923	341 197	307 206	307 206	307 206	307 206	147 537	147 537	147 537	147 537	116 708	116 708	116 708	116 708
201602	35	10 141	71 367	160 956	264 242	202 010	416 172	246 795	536 249	818 321	671 599	544 917	544 917	490 631	490 631	490 631	245 315	235 627	235 627	235 627	235 627	186 391	186 391	186 391	186 391
2016Q3	22	2.5	94 668	205 067	179 295	214 771	169 535	197 464	155 428	206 635	473 700	473 700	473 700	426 509	426 509	213 254	213 254	204 832	204 832	204 832	204 832	162 031	162 031	162 031	162 031
2016Q4	14	29	157 250	157 366	254 248	179 571	327 343	158 566	384 037	294 175	294 175	294 175	294 175	264 869	132 434	132 434	132 434	127 204	127 204	127 204	127 204	100 624	100 624	100 624	100 624
2017Q1	19		122 431	174 172	472 382	240 410	323 718	196 024	444 177	402 689	402 689	402 689	402 689	181 286	181 286	181 286	181 286	174 126	174 126	174 126	174 126	137 741	137 741	137 741	137 741
201702	28	9 506	167 627	184 879	378 303	319 302	436 388	657 167	657 167	595 784	595 784	595 784	297 892	268 215	268 215	268 215	268 215	257 623	257 623	257 623	257 623	203 791	203 791	203 791	203 791
2017Q3	17	750	30 939	88 216	177 929	181 238	402 440	402 440	402 440	364 851	364 851	182 425	182 425	164 252	164 252	164 252	164 252	157 765	157 765	157 765	157 765	124 799	124 799	124 799	124 799
2017Q4	11	910	13 384	271 321	234 524	262 652	262 652	262 652	262 652	238 119	119 059	119 059	119 059	107 198	107 198	107 198	107 198	102 965	102 965	102 965	102 965	81 450	81 450	81 450	81 450
2018Q1	15	-	1 706	89 268	343 618	361 255	361 255	361 255	361 255	163 756	163 756	163 756	163 756	147 442	147 442	147 442	147 442	141 619	141 619	141 619	141 619	112 027	112 027	112 027	112 027
2018Q2	15	S 100	26 518	346 586	346 586	364 376	364 376	364 376	182 188	165 171	165 171	165 171	165 171	148 716	148 716	148 716	148 716	142 843	142 843	142 843	142 843	112 995	112 995	112 995	112 995
201803	19	8	442 801	442 801	442 801	465 529	465 529	232 764	232 764	211 023	211 023	211 023	211 023	190 000	190 000	190 000	190 000	182 497	182 497	182 497	182 497	144 363	144 363	144 363	144 363
Total	556																								

As of September 30, 2018

NY MIF for Fund data; calculated diagonals based on Exhibit 6 Indicated Ultimate Severity Note: 3rd Qtr 2017 diagonal data adjusted to account for no payments made in September

Exhibit 5

New York Department of Financial Services Quarterly Analysis of New York Medical Indemnity Fund Projected Incremental Nominal Payments per Participant by Admittance Quarter

Exhibit 5 Page 2

Admittance	ř.										Inc	remental Ber	nefits Paid by	Fund Partic	ipation Quar	ter											
Quarter	Participants	Q25	Q26	Q27	Q28	Q29	Q30	Q31	Q32	Q33	Q34	Q35	Q36	Q37	Q38	Q39	Q40	Q41	Q42	Q43	Q44	Q45	Q46	Q47	Q48	Q49	Q50
2011Q4	11	56 849	144 337	106 913	98 308	79 600	79 600	79 600	79 600	76 972	38 486	38 486	38 486	39 569	39 569	39 569	39 569	41 012	41 012	41 012	41 012	43 111	43 111	43 111	43 111	45 250	45 250
2012Q1	11	160 512	607 638	42 285	43 277	44 471	44 471	44 471	44 471	21 502	21 502	21 502	21 502	22 107	22 107	22 107	22 107	22 913	22 913	22 913	22 913	24 085	24 085	24 085	24 085	25 280	25 280
2012Q2	15	516 684	435 265	393 920	393 920	404 793	404 793	404 793	202 397	195 713	195 713	195 713	195 713	201 221	201 221	201 221	201 221	208 561	208 561	208 561	208 561	219 233	219 233	219 233	219 233	230 110	230 110
2012Q3	25	331 539	326 908	326 908	326 908	335 932	335 932	167 966	167 966	162 419	162 419	162 419	162 419	166 990	166 990	166 990	166 990	173 082	173 082	173 082	173 082	181 938	181 938	181 938	181 938	190 965	190 965
2012Q4	38	1 152 095	1 152 095	1 152 095	1 152 095	1 183 896	591 948	591 948	591 948	572 402	572 402	572 402	572 402	588 509	588 509	588 509	588 509	609 977	609 977	609 977	609 977	641 190	641 190	641 190	641 190	673 003	673 003
2013Q1	5	138 444	138 444	138 444	138 444	71 133	71 133	71 133	71 133	68 784	68 784	68 784	68 784	70 720	70 720	70 720	70 720	73 299	73 299	73 299	73 299	77 050	77 050	77 050	77 050	80 873	80 873
2013Q2	30	227 964	227 964	227 964	113 982	117 128	117 128	117 128	117 128	113 260	113 260	113 260	113 260	116 447	116 447	116 447	116 447	120 695	120 695	120 695	120 695	126 872	126 872	126 872	126 872	133 166	133 166
2013Q3	26	329 901	329 901	164 950	164 950	169 504	169 504	169 504	169 504	163 906	163 906	163 906	163 906	168 519	168 519	168 519	168 519	174 666	174 666	174 666	174 666	183 604	183 604	183 604	183 604	192 713	192 713
2013Q4	8	89 414	44 707	44 707	44 707	45 941	45 941	45 941	45 941	44 424	44 424	44 424	44 424	45 674	45 674	45 674	45 674	47 340	47 340	47 340	47 340	49 763	49 763	49 763	49 763	52 231	52 231
2014Q1	17	168 410	168 410	168 410	168 410	173 059	173 059	173 059	173 059	167 344	167 344	167 344	167 344	172 053	172 053	172 053	172 053	178 329	178 329	178 329	178 329	187 455	187 455	187 455	187 455	196 755	196 755
2014Q2	25	187 234	187 234	187 234	187 234	192 402	192 402	192 402	192 402	186 049	186 049	186 049	186 049	191 284	191 284	191 284	191 284	198 262	198 262	198 262	198 262	208 407	208 407	208 407	208 407	218 747	218 747
2014Q3	20	223 830	223 830	223 830	223 830	230 008	230 008	230 008	230 008	222 413	222 413	222 413	222 413	228 672	228 672	228 672	228 672	237 013	237 013	237 013	237 013	249 142	249 142	249 142	249 142	261 503	261 503
2014Q4	19	139 609	139 609	139 609	139 609	143 463	143 463	143 463	143 463	138 726	138 726	138 726	138 726	142 629	142 629	142 629	142 629	147 832	147 832	147 832	147 832	155 397	155 397	155 397	155 397	163 107	163 107
2015Q1	26	144 030	144 030	144 030	144 030	148 005	148 005	148 005	148 005	143 118	143 118	143 118	143 118	147 145	147 145	147 145	147 145	152 513	152 513	152 513	152 513	160 317	160 317	160 317	160 317	168 271	168 271
2015Q2	31	303 871	303 871	303 871	303 871	312 259	312 259	312 259	312 259	301 948	301 948	301 948	301 948	310 445	310 445	310 445	310 445	321 769	321 769	321 769	321 769	338 235	338 235	338 235	338 235	355 016	355 016
2015Q3	16	59 606	59 606	59 606	59 606	61 252	61 252	61 252	61 252	59 229	59 229	59 229	59 229	60 896	60 896	60 896	60 896	63 117	63 117	63 117	63 117	66 347	66 347	66 347	66 347	69 639	69 639
2015Q4	20	123 614	123 614	123 614	123 614	127 026	127 026	127 026	127 026	122 832	122 832	122 832	122 832	126 288	126 288	126 288	126 288	130 895	130 895	130 895	130 895	137 593	137 593	137 593	137 593	144 420	144 420
2016Q1	18	116 839	116 839	116 839	116 839	120 064	120 064	120 064	120 064	116 099	116 099	116 099	116 099	119 366	119 366	119 366	119 366	123 720	123 720	123 720	123 720	130 051	130 051	130 051	130 051	136 504	136 504
2016Q2	35	186 600	186 600	186 600	186 600	191 751	191 751	191 751	191 751	185 419	185 419	185 419	185 419	190 637	190 637	190 637	190 637	197 591	197 591	197 591	197 591	207 702	207 702	207 702	207 702	218 007	218 007
2016Q3	22	162 213	162 213	162 213	162 213	166 690	166 690	166 690	166 690	161 186	161 186	161 186	161 186	165 722	165 722	165 722	165 722	171 767	171 767	171 767	171 767	180 557	180 557	180 557	180 557	189 515	189 515
2016Q4	14	100 737	100 737	100 737	100 737	103 517	103 517	103 517	103 517	100 099	100 099	100 099	100 099	102 916	102 916	102 916	102 916	106 670	106 670	106 670	106 670	112 128	112 128	112 128	112 128	117 692	117 692
2017Q1	19	137 896	137 896	137 896	137 896	141 702	141 702	141 702	141 702	137 023	137 023	137 023	137 023	140 879	140 879	140 879	140 879	146 018	146 018	146 018	146 018	153 490	153 490	153 490	153 490	161 105	161 105
2017Q2	28	204 019	204 019	204 019	204 019	209 650	209 650	209 650	209 650	202 728	202 728	202 728	202 728	208 432	208 432	208 432	208 432	216 036	216 036	216 036	216 036	227 090	227 090	227 090	227 090	238 357	238 357
2017Q3	17	124 938	124 938	124 938	124 938	128 387	128 387	128 387	128 387	124 148	124 148	124 148	124 148	127 641	127 641	127 641	127 641	132 297	132 297	132 297	132 297	139 067	139 067	139 067	139 067	145 967	145 967
2017Q4	11	81 541	81 541	81 541	81 541	83 792	83 792	83 792	83 792	81 025	81 025	81 025	81 025	83 305	83 305	83 305	83 305	86 344	86 344	86 344	86 344	90 762	90 762	90 762	90 762	95 265	95 265
2018Q1	15	112 152	112 152	112 152	112 152	115 248	115 248	115 248	115 248	111 443	111 443	111 443	111 443	114 579	114 579	114 579	114 579	118 758	118 758	118 758	118 758	124 835	124 835	124 835	124 835	131 029	131 029
2018Q2	15	113 121	113 121	113 121	113 121	116 244	116 244	116 244	116 244	112 405	112 405	112 405	112 405	115 568	115 568	115 568	115 568	119 784	119 784	119 784	119 784	125 914	125 914	125 914	125 914	132 161	132 161
2018Q3	19	144 524	144 524	144 524	144 524	148 514	148 514	148 514	148 514	143 610	143 610	143 610	143 610	147 651	147 651	147 651	147 651	153 037	153 037	153 037	153 037	160 868	160 868	160 868	160 868	168 849	168 849

Total

As of September 30, 2018

NY MIF for Fund data; calculated diagonals based on Exhibit 6 Indicated Ultimate Severity Note: 3rd Otr 2017 diagonal data adjusted to account for no payments made in September

New York Department of Financial Services

Exhibit 5 Quarterly Analysis of New York Medical Indemnity Fund Page 3

Projected Incremental Nominal Payments per Participant by Admittance Quarter As of September 30, 2018

imittance	17:									Increme	ental Benefit	s Paid by Fur	d Participat	on Quarter							
Quarter	Participants	Q51	Q52	Q53	Q54	Q55	Q56	Q57	Q58	Q59	Q60	Q61	Q62	Q63	Q64	Q65	Q66	Q67	Q68	After Q68	Total
2011Q4	11	45 250	45 250	48 879	48 879	48 879	48 879	47 560	47 560	47 560	47 560	47 958	47 958	47 958	47 958	48 454	48 454	48 454	48 454	15 422 040	19 062 755
2012Q1	11	25 280	25 280	27 308	27 308	27 308	27 308	26 571	26 571	26 571	26 571	26 793	26 793	26 793	26 793	27 071	27 071	27 071	27 071	8 616 059	11 368 137
201202	15	230 110	230 110	248 565	248 565	248 565	248 565	241 857	241 857	241 857	241 857	243 882	243 882	243 882	243 882	246 404	246 404	246 404	246 404	78 425 985	97 440 396
2012Q3	25	190 965	190 965	206 280	206 280	206 280	206 280	200 713	200 713	200 713	200 713	202 394	202 394	202 394	202 394	204 487	204 487	204 487	204 487	65 084 531	80 404 225
2012Q4	38	673 003	673 003	726 977	726 977	726 977	726 977	707 357	707 357	707 357	707 357	713 281	713 281	713 281	713 281	720 657	720 657	720 657	720 657	229 372 107	283 710 033
2013Q1	5	80 873	80 873	87 359	87 359	87 359	87 359	85 001	85 001	85 001	85 001	85 713	85 713	85 713	85 713	86 599	86 599	86 599	86 599	27 563 069	33 975 512
2013Q2	30	133 166	133 166	143 846	143 846	143 846	143 846	139 964	139 964	139 964	139 964	141 136	141 136	141 136	141 136	142 595	142 595	142 595	142 595	45 385 573	55 819 978
2013Q3	26	192 713	192 713	208 169	208 169	208 169	208 169	202 551	202 551	202 551	202 551	204 247	204 247	204 247	204 247	206 359	206 359	206 359	206 359	65 680 390	80 331 052
2013Q4	8	52 231	52 231	56 420	56 420	56 420	56 420	54 898	54 898	54 898	54 898	55 357	55 357	55 357	55 357	55 930	55 930	55 930	55 930	17 801 480	21 768 475
2014Q1	17	196 755	196 755	212 535	212 535	212 535	212 535	206 799	206 799	206 799	206 799	208 531	208 531	208 531	208 531	210 687	210 687	210 687	210 687	67 057 895	82 810 901
201402	25	218 747	218 747	236 291	236 291	236 291	236 291	229 914	229 914	229 914	229 914	231 839	231 839	231 839	231 839	234 236	234 236	234 236	234 236	74 553 268	90 791 967
2014Q3	20	261 503	261 503	282 475	282 475	282 475	282 475	274 852	274 852	274 852	274 852	277 153	277 153	277 153	277 153	280 019	280 019	280 019	280 019	89 125 133	109 131 489
2014Q4	19	163 107	163 107	176 188	176 188	176 188	176 188	171 433	171 433	171 433	171 433	172 869	172 869	172 869	172 869	174 656	174 656	174 656	174 656	55 589 966	68 341 878
2015Q1	26	168 271	168 271	181 767	181 767	181 767	181 767	176 861	176 861	176 861	176 861	178 342	178 342	178 342	178 342	180 186	180 186	180 186	180 186	57 350 064	70 781 939
201502	31	355 016	355 016	383 488	383 488	383 488	383 488	373 138	373 138	373 138	373 138	376 263	376 263	376 263	376 263	380 154	380 154	380 154	380 154	120 996 213	148 525 834
2015Q3	16	69 639	69 639	75 224	75 224	75 224	75 224	73 194	73 194	73 194	73 194	73 807	73 807	73 807	73 807	74 570	74 570	74 570	74 570	23 734 253	29 867 995
2015Q4	20	144 420	144 420	156 002	156 002	156 002	156 002	151 792	151 792	151 792	151 792	153 063	153 063	153 063	153 063	154 646	154 646	154 646	154 646	49 220 959	60 294 649
2016Q1	18	136 504	136 504	147 451	147 451	147 451	147 451	143 472	143 472	143 472	143 472	144 673	144 673	144 673	144 673	146 169	146 169	146 169	146 169	46 523 099	56 737 228
2016Q2	35	218 007	218 007	235 491	235 491	235 491	235 491	229 135	229 135	229 135	229 135	231 054	231 054	231 054	231 054	233 443	233 443	233 443	233 443	74 300 858	91 421 142
2016Q3	22	189 515	189 515	204 714	204 714	204 714	204 714	199 189	199 189	199 189	199 189	200 857	200 857	200 857	200 857	202 934	202 934	202 934	202 934	64 590 235	78 202 546
2016Q4	14	117 692	117 692	127 130	127 130	127 130	127 130	123 699	123 699	123 699	123 699	124 735	124 735	124 735	124 735	126 025	126 025	126 025	126 025	40 111 561	49 461 523
2017Q1	19	161 105	161 105	174 025	174 025	174 025	174 025	169 329	169 329	169 329	169 329	170 747	170 747	170 747	170 747	172 512	172 512	172 512	172 512	54 907 629	67 283 210
2017Q2	28	238 357	238 357	257 474	257 474	257 474	257 474	250 525	250 525	250 525	250 525	252 623	252 623	252 623	252 623	255 235	255 235	255 235	255 235	81 236 743	99 139 516
2017Q3	17	145 967	145 967	157 673	157 673	157 673	157 673	153 418	153 418	153 418	153 418	154 703	154 703	154 703	154 703	156 303	156 303	156 303	156 303	49 748 327	60 494 705
2017Q4	11	95 265	95 265	102 905	102 905	102 905	102 905	100 128	100 128	100 128	100 128	100 966	100 966	100 966	100 966	102 011	102 011	102 011	102 011	32 468 134	39 832 800
2018Q1	15	131 029	131 029	141 537	141 537	141 537	141 537	137 718	137 718	137 718	137 718	138 871	138 871	138 871	138 871	140 307	140 307	140 307	140 307	44 657 149	54 342 049
2018Q2	15	132 161	132 161	142 760	142 760	142 760	142 760	138 907	138 907	138 907	138 907	140 070	140 070	140 070	140 070	141 519	141 519	141 519	141 519	45 042 872	54 910 582
2018Q3	19	168 849	168 849	182 391	182 391	182 391	182 391	177 469	177 469	177 469	177 469	178 955	178 955	178 955	178 955	180 805	180 805	180 805	180 805	57 547 109	70 330 324
Total	556																		T	otal thru 2018Q3	2 066 582 840

NY MIF for Fund data; calculated diagonals based on Exhibit 6 Indicated Ultimate Severity Note: 3rd Qtr 2017 diagonal data adjusted to account for no payments made in September

New York Department of Financial Services Quarterly Analysis of New York Medical Indemnity Fund Projected Incremental Discounted Payments per Participant by Admittance Quarter As of September 30, 2018

Exhibit 5 Page 4

Admittance											In	cremental Ber	nefits Paid by	Fund Partic	ipation Qua	rter									
Quarter	Participants	01	02	03	04	05	Q6	07	08	09	010	011	012	013	014	015	016	017	018	019	020	021	022	023	024
2011Q4	11	- 2	3,146	94,260	144,173	27,926	42,167	22,720	101,483	69,656	29,373	28,827	54,812	47,626	27,564	48,782	108,661	51,481	28,752	49,678	50,087	55,775	59,762	69,834	59,758
2012Q1	11	9	11,909	28,215	15,444	3,802	9,275	24,942	29,365	45,050	65,147	33,607	38,857	22,710	17,639	19,004	47,555	8,050	8,287	14,368	40,610	65,249	105,081	141,372	30,423
2012Q2	15	717	213,939	222,675	216,063	220,760	219,402	284,456	287,128	360,835	337,540	310,577	284,497	328,790	369,738	355,414	322,973	388,125	349,296	336,954	375,984	440,301	426,941	348,845	713,715
2012Q3	25	17,222	58,895	119,468	117,755	160,748	148,012	211,218	300,445	433,929	286,997	349,458	267,625	302,467	229,506	226,706	256,203	321,808	307,643	238,399	314,347	389,016	261,971	507,772	414,951
2012Q4	38	371	75,588	146,333	431,812	623,934	520,889	1,045,294	1,180,508	1,165,671	1,148,800	1,218,933	894,490	978,263	927,857	1,354,514	1,174,223	906,524	1,038,009	1,779,355	1,525,926	763,402	1,540,636	776,503	1,738,563
2013Q1	5	2	780	10,857	36,713	37,090	86,384	177,708	162,554	132,023	136,890	119,318	117,497	87,645	124,918	149,075	110,923	132,056	159,165	175,258	130,412	161,152	221,890	103,938	137,439
2013Q2	30	39	41,406	67,708	78,441	109,369	161,013	217,746	181,675	116,207	135,157	197,202	256,410	167,023	273,743	215,624	191,285	285,507	246,411	140,344	384,275	245,332	288,796	226,307	224,915
2013Q3	26	2	9,394	89,664	176,462	348,379	366,278	407,351	431,269	361,886	366,426	311,761	270,692	340,485	303,320	281,603	325,761	129,991	233,702	141,831	116,773	162,384	327,504	325,489	323,486
2013Q4	8	60	15,787	22,442	52,010	55,080	37,953	152,406	42,227	41,285	68,386	120,264	105,891	45,872	73,694	99,640	75,194	92,384	91,257	108,478	53,984	88,764	88,218	87,675	87,135
2014Q1	17	602	39,529	100,258	166,996	143,474	269,659	282,592	372,432	227,482	404,028	331,801	364,447	363,952	550,020	436,798	424,367	461,052	280,450	434,155	422,698	332,315	330,270	328,237	326,217
2014Q2	25	30,945	132,707	205,442	230,289	335,796	222,383	350,374	280,346	272,353	327,022	254,665	265,346	465,824	240,840	205,985	367,940	223,774	313,120	469,945	467,053	367,186	364,926	362,680	180,224
2014Q3	20	24,460	105,657	644,449	392,488	282,863	305,247	296,763	249,677	377,991	264,554	351,669	427,155	460,362	370,354	783,163	174,676	389,194	561,799	558,342	554,905	436,253	433,568	215,450	214,124
2014Q4	19	1,609	73,351	103,984	172,768	198,623	159,203	193,955	254,713	264,161	336,275	355,696	334,321	362,678	337,740	244,266	347,343	350,411	348,254	346,111	343,981	270,429	134,382	133,555	132,734
2015Q1	26	3,902	118,971	137,048	184,125	195,370	230,680	288,099	212,728	354,753	339,026	219,468	632,582	364,574	248,757	370,420	376,369	359,281	357,069	354,872	352,688	138,637	137,784	136,936	136,093
2015Q2	31	137,049	402,726	435,224	352,996	410,257	523,451	381,714	661,892	618,164	459,971	456,194	825,441	549,361	790,790	794,057	789,170	753,339	748,703	744,095	369,758	290,695	288,906	287,128	285,361
2015Q3	16	CONSTRUCTION OF	30,164	103,507	80,558	69,794	91,758	68,778	223,018	175,695	297,615	259,387	244,576	381,432	155,760	154,801	153,849	146,863	145,960	72,531	72,084	56,671	56,322	55,975	55,631
2015Q4	20	3,829	102,088	91,181	172,019	321,337	211,106	252,349	180,709	145,837	282,289	316,999	306,819	323,021	321,033	319,057	317,093	302,696	150,417	149,491	148,571	116,803	116,084	115,370	114,660
2016Q1	18	210	16,754	185,361	164,559	176,678	222,131	265,022	151,593	251,157	135,105	240,923	339,097	303,436	301,569	299,713	297,869	142,172	141,297	140,428	139,563	109,721	109,046	108,375	107,708
2016Q2	35	10,141	71,367	160,956	264,242	202,010	416,172	246,795	536,249	818,321	671,599	541,564	538,231	481,628	478,664	475,718	236,395	225,662	224,273	222,893	221,521	174,155	173,083	172,018	170,959
2016Q3	22		94,668	205,067	179,295	214,771	169,535	197,464	155,428	206,635	470,785	467,888	465,008	416,106	413,545	205,500	204,235	194,962	193,763	192,570	191,385	150,462	149,536	148,616	147,701
2016Q4	14	15	157,250	157,366	254,248	179,571	327,343	158,566	384,037	292,365	290,566	288,777	287,000	256,818	127,619	126,833	126,053	120,330	119,589	118,853	118,122	92,864	92,293	91,725	91,160
2017Q1	19	200	122,431	174,172	472,382	240,410	323,718	196,024	441,443	397,747	395,300	392,867	390,449	174,694	173,619	172,550	171,488	163,702	162,695	161,694	160,698	126,337	125,560	124,787	124,019
2017Q2	28	9,506	167,627	184,879	378,303	319,302	436,388	653,123	649,103	584,852	581,253	577,676	287,060	256,872	255,291	253,720	252,159	240,710	239,228	237,756	236,293	185,768	184,624	183,488	182,359
2017Q3	17	750	30,939	88,216	177,929	181,238	399,964	397,502	395,056	355,952	353,761	175,792	174,710	156,337	155,375	154,419	153,468	146,500	145,599	144,703	143,812	113,062	112,366	111,674	110,987
2017Q4	11	910	13,384	271,321	234,524	261,035	259,429	257,832	256,246	230,882	114,730	114,024	113,323	101,405	100,781	100,161	99,544	95,025	94,440	93,859	93,281	73,335	72,884	72,435	71,990
2018Q1	15	- 7	1,706	89,268	341,504	356,823	354,627	352,444	350,275	157,802	156,831	155,865	154,906	138,616	137,763	136,915	136,072	129,894	129,095	128,300	127,511	100,246	99,629	99,016	98,406
2018Q2	15	9	26,518	344,453	342,333	357,690	355,488	353,301	175,563	158,185	157,212	156,244	155,283	138,953	138,097	137,248	136,403	130,210	129,408	128,612	127,820	100,489	99,871	99,256	98,645
2018Q3	19	- 1	440,076	437,368	434,676	454,175	451,380	224,301	222,920	200,855	199,619	198,390	197,169	176,434	175,348	174,269	173,197	165,333	164,316	163,304	162,299	127,596	126,811	126,030	125,254

Sources

556

NY MIF for Fund data; calculated diagonals based on Exhibit 6, Indicated Ultimate Severity and a discount factor of 2.5% Note 3rd Qtr 2017 diagonal data adjusted to account for no payments made in September

New York Department of Financial Services

Quarterly Analysis of New York Medical Indemnity Fund

Projected Incremental Discounted Payments per Participant by Admittance Quarter

As of September 30, 2018

Admittance	•6											Inc	remental Be	nefits Paid b	Fund Partic	ipation Quar	rter										
Quarter	<u>Participants</u>	025	026	027	028	029	030	031	032	033	034	035	036	037	038	Q39	040	041	042	Q43	044	045	046	047	048	049	050
2011Q4	11	56,849	144,337	106,913	98,308	79,110	78,624	78,140	77,659	74,632	37,087	36,858	36,631	37,430	37,200	36,971	36,744	37,850	37,617	37,385	37,155	38,816	38,577	38,340	38,104	39,748	39,504
2012Q1	11	160,512	607,638	42,285	43,011	43,926	43,655	43,387	43,120	20,720	20,592	20,465	20,339	20,783	20,655	20,528	20,402	21,016	20,887	20,758	20,630	21,552	21,420	21,288	21,157	22,070	21,934
201202	15	516,684	435,265	391,495	389,086	397,366	394,920	392,490	195,037	187,436	186,283	185,136	183,997	188,010	186,853	185,703	184,560	190,116	188,946	187,783	186,627	194,970	193,770	192,578	191,393	199,652	198,423
2012Q3	25	331,539	324,896	322,897	320,909	327,738	325,721	161,858	160,862	154,593	153,642	152,696	151,757	155,067	154,112	153,164	152,221	156,803	155,838	154,879	153,926	160,807	159,817	158,834	157,856	164,669	163,655
2012Q4	38	1,145,005	1,137,958	1,130,955	1,123,995	1,147,913	570,424	566,914	563,425	541,467	538,135	534,823	531,532	543,126	539,783	536,461	533,160	549,208	545,828	542,469	539,131	563,231	559,765	556,320	552,896	576,757	573,207
2013Q1	5	136,746	135,904	135,068	134,236	68,546	68,125	67,705	67,289	64,666	64,268	63,873	63,480	64,864	64,465	64,068	63,674	65,591	65,187	64,786	64,387	67,266	66,852	66,440	66,031	68,881	68,457
201302	30	223,781	222,404	221,035	109,837	112,175	111,484	110,798	110,116	105,825	105,174	104,526	103,883	106,149	105,496	104,846	104,201	107,338	106,677	106,021	105,368	110,078	109,401	108,728	108,059	112,722	112,028
2013Q3	26	321,854	319,874	158,953	157,974	161,336	160,343	159,356	158,376	152,203	151,267	150,336	149,411	152,670	151,730	150,796	149,868	154,379	153,429	152,485	151,547	158,321	157,347	156,378	155,416	162,123	161,125
2013Q4	8	86,696	43,081	42,816	42,553	43,458	43,191	42,925	42,661	40,998	40,746	40,495	40,246	41,124	40,871	40,619	40,369	41,584	41,328	41,074	40,821	42,646	42,384	42,123	41,863	43,670	43,401
2014Q1	17	162,286	161,288	160,295	159,308	162,698	161,697	160,702	159,713	153,489	152,544	151,605	150,672	153,959	153,011	152,070	151,134	155,683	154,725	153,773	152,826	159,658	158,676	157,699	156,729	163,492	162,486
2014Q2	25	179,315	178,212	177,115	176,025	179,771	178,664	177,565	176,472	169,595	168,551	167,514	166,483	170,114	169,067	168,027	166,993	172,019	170,961	169,909	168,863	176,412	175,326	174,247	173,175	180,648	179,536
2014Q3	20	213,044	211,733	210,430	209,135	213,585	212,271	210,965	209,666	201,495	200,255	199,023	197,798	202,112	200,869	199,632	198,404	204,376	203,118	201,868	200,626	209,594	208,304	207,023	205,748	214,627	213,307
2014Q4	19	132,064	131,252	130,444	129,641	132,400	131,585	130,775	129,970	124,905	124,136	123,372	122,613	125,288	124,517	123,750	122,989	126,691	125,911	125,136	124,366	129,926	129,126	128,331	127,542	133,046	132,227
2015Q1	26	135,407	134,574	133,746	132,923	135,751	134,916	134,085	133,260	128,067	127,279	126,495	125,717	128,459	127,669	126,883	126,102	129,898	129,098	128,304	127,514	133,214	132,395	131,580	130,770	136,413	135,574
2015Q2	31	283,922	282,175	280,438	278,712	284,643	282,891	281,150	279,420	268,530	266,878	265,236	263,603	269,353	267,695	266,048	264,411	272,370	270,693	269,027	267,372	279,324	277,605	275,897	274,199	286,032	284,271
2015Q3	16	55,351	55,010	54,671	54,335	55,491	55,150	54,810	54,473	52,350	52,028	51,708	51,389	52,510	52,187	51,866	51,547	53,098	52,772	52,447	52,124	54,454	54,119	53,786	53,455	55,762	55,419
2015Q4	20	114,081	113,379	112,682	111,988	114,371	113,667	112,968	112,273	107,897	107,233	106,573	105,917	108,228	107,562	106,900	106,242	109,440	108,766	108,097	107,432	112,234	111,543	110,857	110,175	114,929	114,222
2016Q1	18	107,165	106,505	105,850	105,199	107,437	106,776	106,119	105,466	101,356	100,732	100,112	99,496	101,666	101,040	100,419	99,801	102,805	102,172	101,543	100,918	105,429	104,781	104,136	103,495	107,961	107,297
2016Q2	35	170,097	169,050	168,010	166,976	170,529	169,480	168,437	167,400	160,876	159,886	158,902	157,924	161,369	160,376	159,389	158,408	163,176	162,172	161,174	160,182	167,343	166,313	165,289	164,272	171,361	170,307
2016Q3	22	146,957	146,052	145,153	144,260	147,330	146,423	145,522	144,626	138,990	138,135	137,285	136,440	139,416	138,558	137,705	136,858	140,977	140,110	139,247	138,390	144,577	143,687	142,803	141,924	148,049	147,137
2016Q4	14	90,701	90,143	89,588	89,036	90,931	90,371	89,815	89,263	85,784	85,256	84,731	84,210	86,047	85,517	84,991	84,468	87,010	86,475	85,943	85,414	89,232	88,683	88,137	87,595	91,375	90,812
2017Q1	19	123,394	122,634	121,880	121,130	123,707	122,946	122,189	121,437	116,705	115,986	115,273	114,563	117,062	116,342	115,626	114,914	118,373	117,645	116,921	116,201	121,395	120,648	119,906	119,168	124,311	123,546
2017Q2	28	181,439	180,323	179,213	178,110	181,900	180,781	179,668	178,563	171,604	170,548	169,498	168,455	172,129	171,070	170,017	168,971	174,057	172,986	171,921	170,863	178,501	177,403	176,311	175,226	182,788	181,663
2017Q3	17	110,427	109,748	109,072	108,401	110,708	110,027	109,349	108,676	104,441	103,798	103,160	102,525	104,761	104,116	103,476	102,839	105,934	105,282	104,634	103,990	108,639	107,971	107,306	106,646	111,248	110,563
2017Q4	11	71,627	71,186	70,748	70,312	71,809	71,367	70,927	70,491	67,744	67,327	66,913	66,501	67,951	67,533	67,118	66,704	68,712	68,289	67,869	67,451	70,467	70,033	69,602	69,174	72,159	71,715
2018Q1 2018Q2	15	97,910	97,308 97,544	96,709 96,944	96,114	98,159 98,397	97,555 97,792	96,954 97,190	96,358 96,592	92,602	92,032	91,466 91,688	90,903	92,886 93,112	92,314	91,746 91,969	91,182	93,926	93,348	92,774	92,203	96,324	95,732 95,964	95,143 95,374	94,557	98,638 98,877	98,031 98,269
CONTRACTOR OF THE PARTY OF THE	19	98,148	S. C.	F145077 S145070	975 S 200	CAST PROPERTY	\$1000 APA 45 52	CONTROL DAVIG	\$600 Angold	32,827	000 0000 0000	A CONT. 1000	Section 1	10 March 10 V E	Part of the second	Part of Contracts		25-24-77-26-26	200000000000000000000000000000000000000	534 305		17.00	11 10 10 10 10 10 10 10 10 10 10 10 10 1		100	100	124,776
2018Q3	19	124,623	123,856	123,094	122,336	124,939	124,171	123,406	122,647	117,867	117,142	116,421	115,704	118,228	117,501	116,777	116,059	119,552	118,817	118,085	117,359	122,605	121,850	121,100	120,355	125,549	124

Source

Total

556

NY MIF for Fund data; calculated diagonals based on Exhibit 6, Indicated Ultimate Severity and a discount factor of 2.5% Note 3rd Qtr 2017 diagonal data adjusted to account for no payments made in September Exhibit 5

Page 5

New York Department of Financial Services Quarterly Analysis of New York Medical Indemnity Fund Projected Incremental Discounted Payments per Participant by Admittance Quarter As of September 30, 2018

Exhibit 5 Page 6

Admittance	•									Increment	al Benefits P	aid by Fund I	Participation	Quarter							
Quarter	Participants	051	052	053	054	055	056	Q57	Q58	059	Ω60	061	Q62	Q63	Q64	Q65	066	Q67	068	After 068	Total
2011Q4	11	39,260	39,019	41,889	41,631	41,375	41,120	39,764	39,519	39,276	39,035	39,119	38,878	38,639	38,401	38,560	38,322	38,087	37,852	5,201,779	8,624,420
2012Q1	11	21,799	21,665	23,259	23,115	22,973	22,832	22,079	21,943	21,808	21,674	21,721	21,587	21,454	21,322	21,410	21,278	21,147	21,017	2,888,270	5,513,047
2012Q2	15	197,202	195,989	210,404	209,109	207,822	206,543	199,732	198,503	197,281	196,067	196,493	195,283	194,082	192,887	193,682	192,490	191,306	190,128	26,128,115	43,933,364
2012Q3	25	162,648	161,647	173,536	172,469	171,407	170,352	164,735	163,721	162,713	161,712	162,063	161,065	160,074	159,089	159,745	158,762	157,785	156,814	21,549,883	35,823,539
2012Q4	38	569,680	566,174	607,817	604,076	600,359	596,664	576,988	573,437	569,908	566,401	567,629	564,136	560,664	557,214	559,511	556,068	552,646	549,245	75,479,110	125,978,012
2013Q1	5	68,036	67,617	72,590	72,144	71,700	71,258	68,909	68,484	68,063	67,644	67,791	67,374	66,959	66,547	66,821	66,410	66,001	65,595	9,014,316	14,946,800
2013Q2	30	111,339	110,653	118,792	118,061	117,335	116,612	112,767	112,073	111,383	110,698	110,938	110,255	109,577	108,902	109,351	108,678	108,010	107,345	14,751,699	24,364,513
2013Q3	26	160,134	159,148	170,854	169,802	168,757	167,719	162,188	161,190	160,198	159,212	159,557	158,575	157,600	156,630	157,275	156,308	155,346	154,390	21,216,756	34,632,428
2013Q4	8	43,134	42,869	46,022	45,739	45,457	45,177	43,688	43,419	43,152	42,886	42,979	42,715	42,452	42,190	42,364	42,104	41,845	41,587	5,715,029	9,334,633
2014Q1	17	161,486	160,492	172,297	171,236	170,183	169,135	163,558	162,551	161,551	160,557	160,905	159,915	158,931	157,952	158,604	157,628	156,658	155,693	21,395,934	35,791,317
2014Q2	25	178,431	177,333	190,376	189,205	188,040	186,883	180,720	179,608	178,503	177,404	177,789	176,695	175,608	174,527	175,246	174,168	173,096	172,031	23,641,066	38,314,475
2014Q3	20	211,994	210,689	226,186	224,794	223,410	222,036	214,714	213,392	212,079	210,774	211,231	209,931	208,639	207,355	208,210	206,929	205,655	204,390	28,087,921	46,154,505
2014Q4	19	131,413	130,604	140,211	139,348	138,490	137,638	133,099	132,280	131,466	130,657	130,940	130,134	129,333	128,538	129,067	128,273	127,484	126,699	17,411,446	28,909,667
2015Q1	26	134,740	133,910	143,760	142,875	141,996	141,122	136,468	135,628	134,794	133,964	134,255	133,428	132,607	131,791	132,335	131,520	130,711	129,906	17,852,185	29,944,322
2015Q2	31	282,522	280,783	301,435	299,580	297,737	295,904	286,147	284,386	282,635	280,896	281,505	279,773	278,051	276,340	277,479	275,771	274,074	272,388	37,432,452	62,038,194
2015Q3	16	55,078	54,739	58,765	58,403	58,044	57,686	55,784	55,441	55,100	54,761	54,879	54,542	54,206	53,872	54,095	53,762	53,431	53,102	7,297,450	12,838,177
2015Q4	20	113,519	112,820	121,119	120,373	119,632	118,896	114,975	114,268	113,565	112,866	113,110	112,414	111,723	111,035	111,493	110,807	110,125	109,447	15,040,582	24,843,279
2016Q1	18	106,637	105,980	113,775	113,075	112,379	111,688	108,005	107,340	106,679	106,023	106,253	105,599	104,949	104,303	104,733	104,089	103,448	102,811	14,128,701	23,101,630
2016Q2	35	169,258	168,217	180,589	179,478	178,374	177,276	171,430	170,375	169,326	168,284	168,649	167,611	166,580	165,555	166,237	165,214	164,198	163,187	22,425,723	37,498,878
2016Q3	22	146,232	145,332	156,021	155,061	154,107	153,159	148,108	147,197	146,291	145,390	145,706	144,809	143,918	143,032	143,622	142,738	141,860	140,987	19,374,858	31,149,963
2016Q4	14	90,254	89,698	96,296	95,703	95,114	94,529	91,411	90,849	90,290	89,734	89,929	89,375	88,825	88,279	88,643	88,097	87,555	87,016	11,958,047	20,130,516
2017Q1	19	122,785	122,030	131,005	130,199	129,398	128,601	124,361	123,595	122,835	122,079	122,343	121,590	120,842	120,098	120,594	119,852	119,114	118,381	16,268,310	26,980,696
2017Q2	28	180,545	179,434	192,631	191,446	190,268	189,097	182,861	181,736	180,617	179,506	179,895	178,788	177,688	176,594	177,322	176,231	175,146	174,069	23,921,107	39,286,330
2017Q3	17	109,883	109,207	117,239	116,518	115,800	115,088	111,293	110,608	109,927	109,251	109,487	108,814	108,144	107,478	107,922	107,257	106,597	105,941	14,558,824	23,703,127
2017Q4	11	71,273	70,835	76,045	75,577	75,112	74,650	72,188	71,744	71,302	70,863	71,017	70,580	70,146	69,714	70,001	69,571	69,142	68,717	9,443,308	15,730,292
2018Q1	15	97,427	96,828	103,950	103,310	102,674	102,042	98,677	98,070	97,466	96,867	97,077	96,479	95,886	95,295	95,688	95,099	94,514	93,933	12,908,532	21,066,199
2018Q2	15	97,664	97,063	104,202	103,561	102,924	102,290	98,917	98,308	97,703	97,102	97,313	96,714	96,119	95,527	95,921	95,331	94,744	94,161	12,939,902	21,221,606
2018Q3	19	124,008	123,245	132,310	131,496	130,687	129,882	125,599	124,826	124,058	123,295	123,562	122,802	122,046	121,295	121,795	121,045	120,301	119,560	16,430,374	27,128,129
Total	556																		Total	al thru 2018Q3	868,982,061

NY MIF for Fund data; calculated diagonals based on Exhibit 6, Indicated Ultimate Severity and a discount factor of 2.5% Note 3rd Qtr 2017 diagonal data adjusted to account for no payments made in September

New York Department of Financial Services

Quarterly Analysis of New York Medical Indemnity Fund

As of September 30, 2018

Expected Fund Payments by Admittance Year - All Participants

Exhibit 6 Page 1

Fiscal Year (1)	Live Births (2)	Admitted Participants (3)	Cumulative Benefit Payments (4)	Expected Benefit Payments (5)	Expected % of Benefits Paid (6)	Development of Current Payments (7)	B-F Indicated Benefit Payments (8)	Selected Ultimate Payments (9)	Indicated Ultimate Severity (10)
2011	239,608	22	3,523,154	44,023,192	8.07%	43,649,920	43,993,064	30,430,893	1,383,222
2012	238,237	86	41,074,521	593,820,790	7.23%	568,335,192	591,978,904	495,530,167	5,761,979
2013	235,956	84	16,156,549	244,593,120	6.39%	252,647,402	245,108,184	240,730,406	2,865,838
2014	237,491	91	18,210,206	369,260,605	5.45%	333,933,698	367,334,144	339,047,271	3,725,794
2015	235,139	85	13,166,725	301,863,952	4.38%	300,603,205	301,808,730	295,425,705	3,475,597
2016	234,832	91	7,923,061	295,919,764	3.22%	245,693,089	294,300,065	286,368,422	3,146,906
2017	233,561	72	2,590,449	198,871,223	1.95%	133,098,928	197,591,124	253,809,071	3,525,126
2018	232,291	34	27,169	112,980,655	0.64%	4,259,521	112,287,188	125,240,906	3,683,556
Total	1,887,114	565	102,671,834	2,161,333,302		1,882,220,955	2,154,401,402	2,066,582,840	3,657,669

Sources:

- (2) Vital Statistics of New York State; adjusted to MIF fiscal year
- (3) Provided by MIF; includes all living and deceased participants admitted through 09/30/18
- (4) Provided by MIF; includes 7.8% load for prescription drugs
- Pinnacle estimate of expected payments and payment distributions based on admittance year (5), (6)
- Col (4) / Col (6) (7)
- (8) $Col(4) + \{Col(5) \times [1-Col(6)]\}$
- (9) From Exhibit 6, Page 2, Col (9)
- (10)Col (9) / Col (3)

New York Department of Financial Services Quarterly Analysis of New York Medical Indemnity Fund

Exhibit 6 Page 2

As of September 30, 2018

Average Payments per Participant by Admittance Quarter

Admittance Quarter (1)	Living Participants (2)	Deceased Participants (3)	Paid For Deceased (4)	% Paid (5)	Estimated Ultimate Severity (6)	Estimated Ultimate Benefits (7)	Selected Severity (8)	Selected Ultimate Benefits (9)
	7202h	20			2 222 252			
2011Q4	11	0	083 993	7.6%	2,001,350	22,014,852	1,732,978	19,062,755
2012Q1	11	0	222222	7.4%	2,000,758	22,008,340	1,033,467	11,368,137
2012Q2	15	1	276,786	7.2%	7,740,081	116,378,006	6,477,574	97,440,396
2012Q3	25	0	17/2227/227	7.0%	3,746,469	93,661,733	3,216,169	80,404,225
2012Q4	38	2	1,382,899	6.8%	8,335,638	318,137,151	7,429,661	283,710,033
2013Q1	5	0	- 2	6.6%	7,797,383	38,986,914	6,795,102	33,975,512
2013Q2	30	0	a proposition and the con-	6.4%	2,085,345	62,560,363	1,860,666	55,819,978
2013Q3	26	1	2,127,253	6.2%	1,894,906	51,394,818	3,007,838	80,331,052
2013Q4	8	0	1/ <u>2</u> /3	6.0%	2,831,354	22,650,831	2,721,059	21,768,475
2014Q1	17	2	955,063	5.7%	4,835,686	83,161,721	4,815,049	82,810,901
2014Q2	25	0	1544	5.5%	3,465,941	86,648,533	3,631,679	90,791,967
2014Q3	20	0	9 .7 4	5.2%	5,684,311	113,686,216	5,456,574	109,131,489
2014Q4	19	0	5 4 0	4.9%	3,995,517	75,914,822	3,596,941	68,341,878
2015Q1	26	1	167,134	4.7%	3,085,466	80,389,259	2,715,954	70,781,939
2015Q2	31	0	414	4.4%	5,159,131	159,933,057	4,791,156	148,525,834
2015Q3	16	0	2.4	4.1%	3,084,021	49,344,334	1,866,750	29,867,995
2015Q4	20	0	단류를	3.8%	3,113,401	62,268,030	3,014,732	60,294,649
2016Q1	18	0		3.5%	2,848,809	51,278,566	3,152,068	56,737,228
2016Q2	35	0	(3)	3.2%	3,010,484	105,366,945	2,612,033	91,421,142
2016Q3	22	0	185	2.9%	2,214,303	48,714,667	3,554,661	78,202,546
2016Q4	14	1	59,455	2.6%	4,255,206	59,632,344	3,528,719	49,461,523
2017Q1	19	0	1771	2.3%	3,527,469	67,021,903	3,541,222	67,283,210
2017Q2	28	1	4,499	1.9%	2,736,948	76,639,044	3,540,536	99,139,516
2017Q3	17	0	######################################	1.6%	1,749,301	29,738,116	3,558,512	60,494,705
2017Q4	11	0	1 4 2	1.3%	3,275,995	36,035,946	3,621,164	39,832,800
2018Q1	15	0	6428	1.0%	3,286,157	49,292,358	3,622,803	54,342,049
201802	15	0	27	0.6%	3,313,491	49,702,372	3,660,705	54,910,582
2018Q3	19	0	132	0.0%	3,332,429	63,316,159	3,701,596	70,330,324
Total	556	9	4,973,089			2,095,877,399		2,066,582,840

Sources:

- Provided by MIF (2) - (4)
- (5) Based on Virginia Birth Fund patterns
- [Exhibit 4, Page 6 Total Col (4)] / Col (5) / Col (2)
- (7) [Col (6) x Col (2)] + Col (4)
- (8) Selected severity for currently living participants (based on Col (6) and prior selected severity)
- [Col (8) x Col (2)] + Col (4)

endermon.	or an arrangement		State		cate According #3 Feb.	TAXABANI SATURNO	Paid Benefits	Compression of the second		The Control of the Co	KOROWOGO	Estimate of
Affiliate	Current		Effective		Years in	Date of Death	Current	Cumulative	Madiental	Incurred	Current	Cumulative Incurred
Number	Age	Gender	Date	Primary Diagnosis/ Injury	MIF	(if applicable)	Quarter 3,146	To Date 148,995	Medicaid	to Date 148,995	Annual Paid 23,839	in 12 Months 172,834
							4,669	70,469	35,221	105,689	15,098	120,788
							24,031	391,466	224777	391,466	60,226	451,692
								276,786	1,631	278,416	123,741	402,157
							27,762	1,023,997	*	1,023,997	151,703	1,175,701
							23,017	218,923 280	*	218,923 280	33,680 45	252,603
							129,977	2,804,237	3	2,804,237	431,421	325 3,235,658
								2,091	8,946	11,038	1,577	12,615
							12	14,454	53	14,454	2,224	16,678
							15,266	105,273	7,885	113,158	16,165	129,324
							Ē	1,417	-	1,417	218	1,635
							334	41,461 148,011	11,723	53,183 148,011	8,182 22,771	61,366 170,781
							144	14,697	1,853	16,550	2,452	19,002
							4,970	94,975	10,875	105,849	15,121	120,971
							3,557	102,225	1407.000.000	102,225	15,144	117,369
							10,281	92,847	最	92,847	13,264	106,110
							49,161 218	1,701,851 288,984	2	1,701,851 288,984	272,296 46,237	1,974,148 335,221
							30,090	312,050	25,289	337,339	51,898	389,237
							-	1,309	8,025	9,334	1,383	10,717
							583	23,406	10,565	33,971	5,226	39,197
							10,552	134,418	6,530	134,418 6,530	21,507 967	155,925 7,498
							3,920	261,715	5	261,715	41,874	303,590
							42.00	9,660	0.00	9,660	1,486	11,146
							94,156	2,166,688 49,944	3,057	2,169,746 49,944	333,807 7,991	2,503,553 57,935
								12,297	*	12,297	1,967	14,264
							1,589	27,519		27,519	4,403	31,922
							200	man di	147	147	23	170
							2,757 10,600	57,210 455,521	9,231	66,442 455,521	9,492 72,883	75,933 528,404
							2,215	47,657	9	47,657	7,060	54,717
							2,213	7,418		7,418	1,187	8,605
							28,678	947,925	65,793	1,013,718	155,957	1,169,675
							14,438	120,056	12	120,056	19,209	139,265
							10,975	137,745	S S	137,745	22,039	159,785
							5,048	78,918 20,660	-	78,918 20,660	11,274 3,306	90,192 23,965
							816	33,911	5	33,911	5,426	39,337
							-	113,469	2	113,469	16,810	130,279
								582		582	86	668
							2,754	93,833 6,136	4,130	97,962	13,995 909	111,957
							6,423	190,980		6,136 190,980	28,293	7,045 219,273
							263	79,956	3	79,956	12,793	92,748
							100/2	171,052	*	171,052	27,368	198,421
							56,996	382,764	-	382,764	61,242	444,006
							21,333	410,138	50,146	460,284	65,755	526,039
							72 4,019	10,385 84,988		10,385 84,988	1,539 13,598	11,924 98,587
							25,336	553,926	22,702	576,628	82,375	659,003
							983	30,333	1	30,333	4,333	34,666
							82,655	749,580	38,552	788,132	121,251	909,384
							-	309	-	309	48	357
							133,395	291 1,657,235	2	291 1,657,235	265,158	338 1,922,392
							90,600	1,508,819	*	1,508,819	251,470	1,760,289
							67,616	1,044,769	2	1,044,769	174,128	1,218,897
							3,837	6,349 108,033	š	6,349	1,016	7,364 126,038
							15,710	130,054		130,054	21,676	151,730
							3,520	28,885	-	28,885	4,814	33,699
							121	322,022	2	322,022	107,341	429,362
							50,224 83,837	619,709 1,235,323	ğ	619,709	103,285 205,887	722,994 1,441,210
							31,139	958,523		1,235,323 958,523	159,754	1,118,276
												1,110,270
							18.545	1,293.067	·	1,293.0671	215.511	1.508 578
							18,545 900	1,293,067 27,702	8	1,293,067 27,702	215,511 4,432	1,508,578 32,135
									÷			1,508,578 32,135 360,779 1,273,053

10000000	VIOLENCE .		State		SMC5CT#D9MFIRE	720000000000000000000000000000000000000	Paid Benefits	UNDERSTANDAME.		1199397704756	82083W3560	Estimate of
Affiliate Number	Current	Gender	Effective Date	Primary Diagnosis/ Injury	Years in MIF	Date of Death (if applicable)	Current Quarter	Cumulative To Date	Medicaid	Incurred to Date	Current Annual Paid	Cumulative Incurred in 12 Months
Number	Me	Gender	Date	Primary Diagnosisy injury	tent	(ii applicable)	Quarter -	15,543	-	15,543	2,591	18,134
							19,609	175,692	- E	175,692	29,282	204,974
							22.2	2,623	2	2,623	437	3,060
							50,317 70,091	88,590 1,283,303	Š	88,590 1,283,303	14,765 213,884	103,355 1,497,183
							32,285	236,928	1	236,928	39,488	276,416
							52,120	855,265	-	855,265	142,544	997,810
							33,176	351,548	2	351,548	58,591	410,139
							21,025 559,237	357,042 4,331,098	-	357,042 4,331,098	59,507 721,850	416,549 5,052,94
							6,915	403,436	(1)	403,436	67,239	470,675
							132,090	2,050,824	*	2,050,824	341,804	2,392,621
							1.5	5,250	150	5,250	875	6,125
							1,208	37,953 10,646	2	37,953 10,646	6,325 1,774	44,278 12,421
							2,883	164,272		164,272	27,379	191,650
							2,003	5,310	2	5,310	885	6,195
							1,026	5,492	-	5,492	915	6,407
							660 174,889	88,473 1,625,100	S:	88,473 1,625,100	14,745 270,850	103,218 1,895,956
							165	58,495	- 677	58,495	9,749	68,245
							1,327	66,359	3	66,359	11,060	77,419
							741	56,014	*	56,014	9,336	65,349
							4,369	165,505	8	165,505	27,584	193,089
							333	9,497 6,916	2-74	9,497 6,916	1,583 1,153	11,080 8,069
							26,418	396,034	ŝ	396,034	66,006	462,040
							61,088	157,740	2	157,740	26,290	184,030
							38,608	1,112,286	Ē.	1,112,286	193,441	1,305,72
							26.250	1,835		1,835	319	2,154
							36,258 18,486	810,188 384,762	<u> </u>	810,188 384,762	140,902 66,915	951,090 451,678
							5,393	72,183	3	72,183	12,554	84,737
							12000	37,475	8	37,475	6,814	44,289
							1,620	25,727		25,727	4,678	30,405
							63,794 1,550	732,373 12,509	-	732,373 12,509	133,159 2,274	865,531 14,784
							2,550	7,400	8	7,400	1,345	8,745
							eros E	2,484	93	2,484	452	2,935
							4,142	71,311	- 3-	71,311	12,966	84,277
							1,473	41,405 3,898	2.	41,405 3,898	7,528 709	48,933 4,607
							146	1,610		1,610	293	1,903
							-	900.000	3		400000	
							5,221	403,645		403,645	73,390	477,035
							1	6,736	2	6,736	1,225	7,960
							719	3,352		3,352	609	3,961
							12	653	57	653	119	77:
							1,243	18,818	*	18,818	3,421	22,239
							33,321	183,153	ŝ	183,153	33,301	216,454
							1,189	216,607	*	216,607	39,383	255,990
							65,008	960,730	5	960,730	174,678	1,135,40
							588	10,159	1.11	10,159	1,847	12,006
							508	1,679	8	1,679	305	1,984
								11,261	2	11,261	2,047	13,308
							8	18,856	1	18,856	3,428	22,285
								1,435		1,435	261	1,696
							94,150	726,211 208,286	<u>a</u>	726,211 208,286	132,038 37,870	858,250 246,156
								-	2	0.00	11000	
							717	93,085	ž.	93,085	17,730	110,816
							6,171	188,366	2	188,366	35,879	224,245
							3,234 4,148	8,405 98,898	*	8,405 98,898	1,601 18,838	10,006 117,735
							4,140	7,086	, p	7,086	1,350	8,436
							157	239	2	239	45	284
							1,505	55,252	- 5	55,252	10,524	65,777
							9,568 9,978	128,103 43,208		128,103 43,208	24,401 8,230	152,504 51,439
							3,376	587	8	587	112	699
							40	16,850	20	16,850	3,210	20,060

Estimate of Cumulative Incurred	Current	Incurred	0.0	Cumulative	Paid Benefits Current	Date of Death	Years in		State Effective		Current	Affiliate
in 12 Months	Annual Paid	to Date	Medicaid	To Date	Quarter	(if applicable)	MIF	Primary Diagnosis/ Injury	Date	Gender	Age	Number
340,878	54,540	286,337	*	286,337	16,512	.W. 205		The second second second				
8,070 1,797	1,291 288	6,779 1,510	3	6,779 1,510	5							
689,596	110,335	579,261		579,261	21,841							
45,346	7,255	38,091	\$	38,091	11,154							
21,610	3,458	18,153	20	18,153	10000000							
376,739	60,278	316,461		316,461	11,752							
85,319 2,694,520	13,651 567,267	71,668 2,127,253	-	71,668 2,127,253	215							
774,073	123,852	650,221	Ē	650,221	56,787							
660	106	554	22	554	-							
26,460	4,234	22,226	(5)	22,226	493							
11,964	1,914	10,050	2	10,050	5							
26,827 192	4,292	22,535 162	-	22,535 162	-							
535,260	89,210	446,050	- 2	446,050	23,456							
18,258	3,043	15,215	2	15,215	125							
5,773	962	4,811	5	4,811	165							
21,820 855,690	3,637 142,615	18,183 713,075	S(18,183 713,075	350 25,696							
10,391	1,732	8,659		8,659	805							
1,325	221	1,104	3	1,104	-							
53,066	8,844	44,222	*	44,222	690							
1,089,870	189,543	900,328	5	900,328	30,845							
82,102 1,294,628	27,367 225,153	54,735 1,069,475		54,735	75 927							
1,294,628	225,153 875	4,154	8	1,069,475 4,154	75,827							
1,913	333	1,580	-	1,580	- 4							
581,170	101,073	480,097	51	480,097	30,564							
		- 8	2	7/4	2							
233,972	40,691 2,335	193,281 11,090	S	193,281 11,090	15,873 186							
13,424 72,390	12,590	59,800	8	59,800	7,468							
	-	33,000	*	33,000	132							
	- 52	12,	\$		22							
2,062,039	358,615	1,703,424	2	1,703,424	125,638							
158,622 66,738	27,586 11,607	131,036 55,132	Ē	131,036 55,132	94,305 608							
254,937	44,337	210,600	-	210,600	26,245							
48,598	8,452	40,146	-	40,146	1,220							
378,817	65,881	312,936	2.	312,936	3,687							
4,354	757	3,597	4 5	3,597	-							
270,329	49,151	221,178	3	221,178	3,439							
270,323	43,131	221,176		221,176	3,439							
15,160	2,756	12,403	-	12,403	- 3							
1,491,642	271,208	1,220,434	외	1,220,434	149,419							
128	23	105	Ē	105								
18,532	3,369	15,162	-	15,162	4,761							
10,375	1,886	8,489	- 5	8,489	191							
164,237	29,861	134,375	2	134,375	6,242							
36,107	6,565	29,542	*	29,542	5000							
328,577 17,132	59,741 3,115	268,836 14,017	2	268,836 14,017	15,765 3,254							
230,869	41,976	188,893	*	188,893	-							
		-	Š	-								
27,935	5,079	22,856		22,856	8,655							
43,459 122,664	7,902 22,303	35,557 100,362	1	35,557 100,362	839 6,597							
717,398	130,436	586,962		586,962	18,197							
221,832	40,333	181,499		181,499	10,447							
280,339	50,971	229,368	20	229,368	24,902							
133,540	24,280	109,260	Š.	109,260	299							
2,032	122 640	1,663	- 20	1,663	20,100							
680,019 534,833	123,640 97,242	556,379 437,591		556,379 437,591	26,164 18,497							
10,316	1,965	8,351	(5) (5)	8,351	-							
527,599 17,038	100,495	427,104		427,104	51,683							
	3,245	13,793		13,793	400.046							
1,439,301 318,276	274,153 60,624	1,165,149 257,652		1,165,149 257,652	103,345 6,750							
310,2/6	2,339	9,942	a: 5	9,942	6,750							
12.281												
12,281 1,284 9,641	245 1,836	1,040 7,804	35	1,040 7,804	359							

Estimate of	80080W0000	11 533 7770		UNDERSONAL PROPERTY.	Paid Benefits	Takayo (arganto area	2400001#3947 Fc		State		VIDEORS CO.	10000000000
Cumulative Incurred in 12 Months	Current Annual Paid	Incurred to Date	Medicaid	Cumulative To Date	Current Quarter	Date of Death (if applicable)	Years in MIF	Orimani Diagnori-/ Intime	Effective	Conde	Current	Affiliate Number
83,0	15,816	67,220	iviedicaid	67,220	22,549	(ii applicable)	MIF	Primary Diagnosis/ Injury	Date	Gender	Age	Number
8,0	1,529	6,497	(P)	6,497								
37,5	7,149	30,382	2)	30,382	801							
137,2	26,135	111,073	5	111,073	20,496							
6,79	1,294	5,499		5,499	264							
8,60 24,64	1,650 4,694	7,012 19,951	8	7,012 19,951	264 31							
77,1	14,700	62,473	ē	62,473	8,143							
221,3	42,158 52	179,172 221	2	179,172 221	10,108							
3,813,4	726,369	3,087,070	8	3,087,070	145,222							
9,1	1,827	195 7,308	<u> </u>	195 7,308	2							
89,5	17,902	71,609		71,609	1,715							
1,134,3	226,878	907,512	2	907,512	110,872							
369,6	73,929	295,716	5	295,716	38,887							
449,7 134,1	89,952 26,826	359,808 107,303	S:	359,808 107,303	25,259 52,094							
2,11	437	1,748	200	1,748	32,034							
106,7	21,352	85,408	3	85,408	<u> </u>							
3	74	295	*	295								
7,75 973,5	1,550 194,713	6,201 778,854	8	6,201 778,854	430 60,788							
298,1	59,637	238,547		238,547	25,082							
473,9	94,799	379,197	8	379,197	1,477							
10,7	2,152	8,608	99	8,608	496							
5,91 245,9	1,196 49,199	4,786 196,798	2	4,786 196,798	218 12,674							
#5125A	2000 PM		(4)	100000	-							
218,5 42,4	51,426 8,936	167,134 33,509	3	167,134 33,509	ā							
418,9	88,193	330,723	Š	330,723	16,433							
241,1	50,770	190,388		190,388	14,861							
7,60	1,600	6,000		6,000	-							
37,3	7,857	29,462	51	29,462	7,413							
2,96	625 128	2,343 480	8	2,343 480	480							
3,21	692	2,594	2	2,594	<i>)</i>							
4,4	942	3,534	99	3,534	GUASAN T							
94,0	19,795	74,229	3	74,229	2,250							
7,4° 18,0°	1,574 3,794	5,903 14,226		5,903 14,226	786 1,004							
681,2	143,412	537,794	ē.	537,794	47,365							
1,193,1	251,189	941,959	2	941,959	99,681							
160,8	33,871	127,016		127,016	16,609							
147,0 174,7	30,948 36,794	116,056 137,977	-	116,056 137,977	8,400 12,371							
504,7	106,263	398,488	3	398,488	84,584							
303,3	63,868	239,504	S .	239,504	17,543							
2,89	609	2,282	2	2,282	ā							
90,9	19,152	71,819	*	71,819	2,967							
172,2	36,256	135,958	Ē.	135,958	2,716							
31,1	6,553	24,573	2	24,573	16,450							
766,9 60,4	170,431 13,432	596,509 47,013	2	596,509 47,013	55,730 3,600							
1,6	360	1 350	20	1,259	8							
10,9	2,422	1,259 8,478	3	8,478	ē							
43,50	9,667	33,834	Š	33,834	1,973							
1,638,3	364,080	1,274,281	- 2	1,440	149,803							
5,8	1,305	4,567	*	4,567	1,217							
281,0	62,456	218,596	8	218,596	14,529							
17,9 3,590,6	3,999 797,927	13,996 2,792,744	2	13,996 2,792,744	584 374,986							
566,5	125,895	440,632	2	440,632	36,094							
67,7	15,066	52,732	99	52,732	23,102							
57,5	12,792	44,773	3	44,773	3,947							
255,1	56,706	198,470		198,470	644							

MADE CANDE DA			State		tatotic menanti lic	Tax ray o Association Revo	Paid Benefits	CONTRACTOR AND		THE ASSESSMENT OF	NOT REAL PROPERTY.	Estimate of
Affiliate Number	Current	Gender	Effective Date	Primary Diagnosis/ Injury	Years in MIF	Date of Death (if applicable)	Current Quarter	Cumulative To Date	Medicaid	Incurred to Date	Current Annual Paid	Cumulative Incurred in 12 Months
							27,809	281,733	*	281,733	80,495	362,228
							43	247	\$	247	71	318
							2	122	Š	122	35	157
								4,601		4,601	1,315	5,916
							1,376	3,273	ē	3,273	935	4,208
							4,487	36,076	5	36,076	10,307	46,383
							3,967	15,184 1,497	- 2	15,184 1,497	4,338 428	19,522 1,924
							-	-	*		100 E	
							46,969 400	379,868 14,691	2	379,868 14,691	108,534 4,197	488,402 18,888
							2,965	19,216	5	19,216	5,913	25,129
							979	65,492	3	65,492	20,151	85,643
							22,959 49	169,833 3,317	-	169,833 3,317	52,256 1,021	222,089 4,338
							4,944	16,291	51	16,291	5,013	21,303
							6,477 215,389	122,150 673,025	-	122,150 673,025	37,585 207,085	159,735 880,109
							34,029	151,379	3	151,379	46,578	197,957
							-	3,654 1,923	*	3,654 1,923	1,124 592	4,778 2,514
							725	15,462	뢒	15,462	4,758	20,220
							57,121	161,388		161,388	49,658	211,046
							16,739	178 436,885	S2 	178 436,885	134,426	233 571,312
							- <i>(ii</i>	200	5	-	1 1	
								33,009 34,277		33,009 34,277	10,156	43,165 45,702
							220	4,625	3	4,625	1,542	6,167
							1,802 20,636	75,247 260,222		75,247 260,222	25,082 86,741	100,330 346,963
							58	11,586	Š	11,586	3,862	15,448
							10,067 26,383	38,350 122,026	-	38,350 122,026	12,783 40,675	51,134 162,702
							20,363	562	ē	562	187	749
							284	4,411 798	*	4,411 798	1,470 266	5,881 1,065
							·	30		30	10	40
							9	127	4		22	
							35,936	297,512	3	297,512	99,171	396,682
							11441030	776		776	259	1,035
							26,296	4,550 417,541	2	4,550 417,541	1,517 139,180	6,067 556,722
							1,090	29,017		29,017	9,672	38,689
							4,062 164,651	55,468 844,928	2	55,468 844,928	18,489 281,643	73,958 1,126,571
							7,310	137,141		137,141	49,869	187,011
							751	8,345	2	8,345	3,034	11,379
								1,366	2	1,366	497	1,863
							2,024	14,903 58,302	<u> </u>	14,903 58,302	5,419 21,201	20,323 79,503
							2,024	1,339	ē.	1,339	487	1,826
							40,265	265,633	2	265,633	96,594	362,227
							34,725 103	367,289 903	2	367,289 903	133,560 328	500,849 1,231
							59,990	179,111	8	179,111	65,131	244,242
							16,891 13,138	135,935 96,101	33	135,935 96,101	49,431 34,946	185,365 131,047
							4,810	33,680	*	33,680	12,247	45,927
							30,654	4,084 225,461	2/	4,084 225,461	1,485 81,986	5,569 307,446
							3,518	81,414		81,414	29,605	111,020
							14,302	56,650	2	56,650	20,600	77,249
							2,353	27,017		27,017	10,807	37,824
							9	614	¥:	614	246	860
								2,572		2,572	1,029	3,601
							3,035	36,825	ŝ	36,825	14,730	51,556 3,135
							538	2,239	*	2,239	896	3,135

WYOCK WAS A	PLANTSONS.		State		tatorian en servicio.	Tarris Association (New York)	Paid Benefits	TOTAL PROGRAM VEHICLE		Per service on	KITA WATER	Estimate of
Affiliate Number	Current	Gender	Effective Date	Primary Diagnosis/ Injury	Years in MIF	Date of Death (if applicable)	Current Quarter	Cumulative To Date	Medicaid	Incurred to Date	Current Annual Paid	Cumulative Incurred in 12 Months
7,000	L. B.C.	CCITACI	Dute	Transit Coopiess of Figure		(785	9,364		9,364	3,746	13,110
								38,024	5	38,024	15,210	53,234
							989	4,706	20	4,706	1,883	6,589
							2,936	27,906	Š	27,906	11,162	39,068
									20	2.007	4 222	4 220
							1,565 27,173	3,097 262,904	Ē	3,097 262,904	1,239 105,162	4,336 368,066
							13,407	66,105	40	66,105	26,442	92,548
							9,651	65,740	55	65,740	26,296	92,036
							53,763	280,324	(4)	280,324	112,130	392,453
							3,302	44,125	*	44,125	17,650	61,775
							23,243	4,664 163,350	5	4,664 163,350	1,866 65,340	6,529 228,690
							=00.75	315	5	315	126	440
							77	843	į	843	337	1,180
							355,408	789,421		789,421	315,768	1,105,189
							48,724	303,605	2	303,605	121,442	425,047
							26,452	318,563		318,563	127,425	445,988
							1,842	41,083	58	41,083	16,433	57,517
							522	7,245 6,177		7,245 6,177	2,898 2,471	10,143 8,648
							14,584	163,328		163,328	65,331	228,659
							40.270	415 425	8	415 425	166 174	F01 C00
							40,279	415,435 7,235	8	415,435 7,235	166,174 2,894	581,608 10,129
							7,299	40,423	-	40,423	16,169	56,592
							· · · · · · · · · · · · · · · · · · ·	1,122	5	1,122	499	1,621
							1	12,726		12,726	5,656	18,382
							12,782	50,221	\$	50,221	22,321	72,542
							164 8,722	11,863 82,430	Š	11,863 82,430	5,272 36,636	17,135 119,066
								100450	- 2	const.		3,175,577
							519	1,852 820	Ē	1,852 820	823 364	2,675
							20	48,697	-	48,697	21,643	70,341
							207	5,694		5,694	2,531	8,224
							9// 32	89	2	89	40	129
							171,735	1,057,335	¥.	1,057,335	469,926	170 1,527,261
							3,000	-	Š		-	234272452
							1 274	2,967		2,967	1,319	A 200
							1,274	1,211	2	1,211	538	4,286 1,750
							887	36,696	-	36,696	16,309	53,005
							Tall	471	9	471	209	680
							189,061	636,889		636,889	318,445	955,334
							985	26,954	3	26,954	13,477	40,431
							31,834	208,725	*	208,725	104,363	313,088
							18,706 600	122,191 4,618	2	122,191 4,618	61,096 2,309	183,287 6,927
								59,455	8	59,455	59,455	118,910
							-	9. 0			5.5	
								15,836	2	15,836	7,918	23,754
							93,939	52,117 172,178	1	52,117 172,178	26,059 86,089	78,176 258,267
							20,296	61,297	20	61,297	30,649	91,946
							810	72,169	Š	72,169	36,085	108,254
							4,310 4,310	30,836 29,716	ğ	30,836 29,716	15,418 14,858	46,254 44,574
							7,387	53,099	2	53,099	30,342	83,441
							10,521	212,691	8	212,691	121,538	334,229
							1,926	13,561	8	13,561	7,749	21,310
							36,476	2,122 421,813	3	2,122 421,813	1,213 241,036	3,335 662,849
							1,087	26,984	- 8	26,984	15,419	42,404
							-	-	90	1775577	470	
							原	24.422	ŝ	5		
							89,793	24,022 364,145		24,022 364,145	13,727 208,083	37,749 572,227
							89,793	304,145		364,145	208,083	5/2,22/

Estimate of		I was a second and			Paid Benefits				State			
Cumulative Incurred in 12 Months	Current Annual Paid	Incurred to Date	Medicaid	Cumulative To Date	Current Quarter	Date of Death (if applicable)	Years in MIF	Primary Diagnosis/ Injury	Effective Date	Gender	Current	Affiliate Number
14,017	5,097	8,920	*	8,920	880	,,		Trimary Diagnosis, injury	Dute	Gender	- Mr	
120,816	43,933	76,883	3	76,883	32,806							
15,559 1,695	5,658	9,901 1,078		9,901 1,078	490							
255,149	92,781	162,367	5	162,367								
8,602	3,128	5,474	20	5,474	242							
	1	臺	Ē	10.	8							
36,716	13,351	23,365	2	23,365	4,623							
120	17/2		29	7/4	8							
19,985	7,994	11,991	*	11,991	2,285							
300	120	180	8	180	180							
721,649 2,338	288,659 935	432,989 1,403	2	432,989 1,403	96,878							
8,099	3,600	4,499		4,499	256							
40.004			2									
40,906 460	16,362 184	24,543 276	3	24,543 276	5,982 276							
		-	*		4-0 <u>2</u> 01							
664,576 38,487	265,831 15,395	398,746 23,092	5	398,746 23,092	102,292							
241,696	96,678	145,018		145,018	7,374 103,629							
41,490	16,596	24,894	ē.	24,894	24,894							
181,525	72,610	108,915		108,915	27,665							
1,733	693	1,040	5	1,040	840							
2,945	1,178	1,767		1,767	225							
34,031 12,119	13,612 4,848	20,419 7,272	1	20,419 7,272	5,791 4,415							
279,961	111,984	167,977	8	167,977	29,039							
			3	8								
	5 <u>4</u>	11172										
1,977	791	1,186	\$	1,186	10							
4,984 10,495	1,994	2,991	2	2,991	2,471							
1,518	4,198 607	6,297 911	8	6,297 911	220 100							
	200	200		4	0.50							
551 238,209	245 105,871	306 132,338		306 132,338	57,047							
250,205	105,871	132,336	-	132,336	57,047							
18,461	8,205	10,256	3	10,256	4,539							
	32											
3,955	1,758	2,197	- 5	2,197	662							
56,405 270,607	25,069	31,336	2	31,336	11,112							
84,182	120,270 37,414	150,337 46,768	8	150,337 46,768	54,887 14,618							
21,407	9,514	11,893	(*)	11,893	212							
55,784	24,793	30,991	ŝ	30,991	15,336							
33,764	24,755	30,331	*	50,551	23,330							
F0.000	22.427	20.000	2	20.000	40.770							
52,036 330	23,127 165	28,909 165		28,909 165	13,772							
30,350	15,175	15,175		15,175	3,052							
	12	-	2	72	-							
42,167	21,083	21,083	2	21,083	6,642							
22,026	11,013	11,013		11,013	8,505							
16,624 850,961	8,312 425,481	8,312 425,481	8	8,312 425,481	4,370 197,712							
484	242	242	*	242	2000-2000							
4,114	2,057	2,057	9.	2,057	2,057							
940 22,159	470 12,662	470 9,497	*	470 9,497	470 9,497							
	100	, re 5	8	27	3							
24,379 1,411	13,931 806	10,448	2	10,448 605	10,448							
14,956	8,546	6,410	- S	6,410	6,410							
13,186	7,535	5,651	91	5,651	5,302							
		75 (=)	-		200							
4,849	2,771	2,078	8	2,078	2,078							

T.			State				Paid Benefits			- 4		Estimate of
Affiliate Number	Current Age	Gender	Effective Date	Primary Diagnosis/ Injury	Years in MIF	Date of Death (if applicable)	Current Quarter	Cumulative To Date	Medicaid	Incurred to Date	Current Annual Paid	Cumulative Incurred in 12 Months
							(#)	W*S	*	(6)		
							3	1	3	§		
							36,390 14,080	37,600 14,080	Š	37,600 14,080	50,134 18,773	87,73- 32,85
						· ·			2	7.1Š.	90.0	90520
							456 8,194	456 8,194	3	456 8,194	912 16,387	1,36 24,58
							2,254	2,254	8	2,254	4,509	6,76
							100		(2)	920	52	32
							296 8,632	296 8,632	*	8,632	593 17,264	88 25,89
							5,361	5,361	2	5,361	10,723	16,08
							200	1,77	51	100		
						£5	å	5.50	-			
							2		2	~		
							8		8	5		
							-	Q+c-	*			
						(3)	in the second	B T ES	3	5		
							-	4.0				
							5	÷		5		
						120		95	-	-		
							12	9/4/4 84-8	[2]	2		
								(1 € =		(2)		
						99	- 2	141	- X	- 8		
										5		
								(+		8		
						46				- 2		
							-	950				
							0	0410	521	2		
9							- 3			- 5		
NYS000000068		N/A	N/	A MedCare Invoice Processing Number				5,037,116	45	5,037,116		
NYS00000000		N/A		A Vendor Invoice Member Number			462,365	2,429,907	3	2,429,907		
UNKNOWN							-	25,232	20	25,232		
Total							9,255,490	102,376,743	322,301	102,699,044		

New York Department of Financial Services Quarterly Analysis of New York Medical Indemnity Fund **Administrative Expense Summary**

	Dollar Amount	<u>Provider</u>	<u>Basis</u>
Prior Admin Expenses: (before 9/1/17)	\$ 809.00	Alicare	Per member per month (pmpm)
As of 9/1/17:	666.00 62.00	Alicare PCG	Per member per month (pmpm) Per member per month (pmpm)
As of 9/1/18:	705.72 64.00	PCG (Enrollment costs) PCG (TPA fees)	Per member per month (pmpm) Per member per month (pmpm)
As of 9/1/19:	609.28 66.00	PCG (Enrollment costs) PCG (TPA fees)	Per member per month (pmpm) Per member per month (pmpm)
As of 9/1/20:	569.74 68.00	PCG (Enrollment costs) PCG (TPA fees)	Per member per month (pmpm) Per member per month (pmpm)
As of 9/1/21:	533.82 70.00	PCG (Enrollment costs) PCG (TPA fees)	Per member per month (pmpm) Per member per month (pmpm)
Years after 9/1/17			
Year 1:	728.00	Fiscal Year Average	Fiscal Year
Year 2:	769.72	752.34	2018/19
Year 3:	675.28	714.63	2019/20
Year 4:	637.74	653.38	2020/21
Year 5:	603.82	617.95	2021/22
Average:	682.91		

Administrative expense details provided by MIF